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Abstract 
 
Meis1 and Prep1 homeodomain-containing transcription factors are essential for the 
normal embryonic development of several tissues and organs. Although they both can 
recruit Pbx at least for some of their biological function using the same homology region, 
the Meis1-Pbx and Prep1-Pbx complexes bind different DNA sequences and play 
opposite roles in tumorigenicity. In cancer, Meis1 has been extensively implicated in 
leukemia and neuroblastoma. Overexpression of Meis1 greatly shortens the latency and 
affects the penetrance of myeloid leukemia induced by Hox genes retroviral transduction. 
Furthermore, Meis1 has essential oncogenic function in all human leukemic MLL-
translocation. Although, Meis1 is strongly suggested for involvement in human 
neuroblastoma and glioma, its function in non-hematological malignancies and solid 
tumors remains poorly defined. In contrast, Prep1 does not accelerate Hox-induced 
leukemogenesis. In fact heterozygous or homozygous Prep1-deficient mice develop 
tumors at high frequency. In mice, Prep1 haploinsufficiency causes spontaneous tumor 
formation and accelerates development of tumors in EµMyc transgenic mice. In human 
tumors, PREP1 is absent or downregulated in a large fraction of tumors including lung, 
breast and colon cancers. Therefore, Prep1 exerts tumor suppressor function in the cell by 
maintaining genomic stability and hence preventing neoplastic transformation. 
Here I show that Meis1 is involved in malignant transformation of Prep1-deficient MEFs 
and that this can be partially rescued by re-expression of Prep1. I demonstrate that the 
Pbx-interacting domain of Prep1 is involved in its tumor suppressor function. Moreover, 
Both Meis1 and Prep1 require Pbx1 for their oncogenic and tumorsppressive functions, 
respectively. Therefore Meis1 and Prep1 do compete for Pbx1 in the context of tumor 
development. Furthermore, I find Meis1 interacts with Ddx3x and Ddx5 RNA helicases, 
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which is perturbed in the presence of Prep1. Together, the presented results suggest that 
Meis1 is a bona-fide oncogene also in non-hematic cells and that Prep1 impairs Meis1 
tumorigenicity by either competing for Pbx1 or preventing its interaction with 
transcriptionally relevant partners.  
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1.1. The Evolution of Cancer 
 
Cancer (neoplasm) is a family of genetic diseases that results from uncontrolled cell 
division and tissue invasiveness (metastasis). The failure to regulate cell proliferation and 
consequent metastasis is caused by dynamic alterations in the genome and epigenome of 
the cancer cells. Somatically acquired abnormalities in DNA sequence and selection lead 
to the alterations of the cancer cell genome. These somatic mutations according to their 
contribution in cancer development may be classified into driver and passenger 
mutations. Driver mutations confer growth advantages to the cancer cells and are 
positively selected during the evolution of the cancer. They tend to cause clonal 
expansion of cancer cells. Passenger mutations are present in a cancer genome as a by-
product of cancer cell development and do not contribute to the cancer development. 
However, they may be associated with a clonal expansion caused by driver mutations 
[1,2,3,4,5,6]. 
A growing body of evidence resulting from the study of epigenetic mechanisms in 
cancer has shown that cancer is not solely a consequence of genetic alteration of the 
cancer-critical genes. Cancer cells have a different epigenome compared to their normal 
counterparts. For instance hypomethylation of cancer cells was one of the first epigenetic  
alterations found in human cancers [6]. Cancer development is a multistep process and it 
requires the accumulation of different mutations during the lifetime of the cancer patient. 
During each step, cells acquire genetic alterations that progressively transform normal 
cells into more malignant ones (Figure 1.1) [1,2,5].  
Cancers are classified into different types according to the type of their original cell, 
including carcinoma (epithelial cell), glioma (glial brain cell), sarcoma (mesenchymal 
cell), lymphoma and leukemia (bone marrow and blood cells), mesothelioma (mesothelial 
Introduction 
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cells that cover the peritoneal and pleural cavities), choriocarcinoma (placenta), and 
germinoma (germ cell of the testes or ovary) [1].  
 
 
Figure 1.1. Somatic mutations occurring from a fertilized egg to a single cell within a 
cancer. Mutations accumulate because of the intrinsic mutation rate during normal cell 
divisions and of the formation of mutations because of exogenous mutagens. Other 
processes may contribute to the cancer development by mutational burden. Passenger 
mutations may be acquired while the cell lineage is phenotypically normal. Driver 
mutations will cause a clonal expansion and resistance to chemotherapy [5]. 
 
1.2. Cancer Critical-Genes 
The term “ cancer-critical genes” includes all genes whose mutations contribute to 
the tumorigenicity. The affected genes are divided into two broad categories, according to 
their functions. Cancer risk may arise either from the activation or inactivation of the 
cancer-critical genes. Genes of the first category, for which a gain-of-function mutation 
drives a cell towards cancer, are called proto-oncogenes; their mutant overactive forms 
are called oncogenes. Genes of the second category, for which a loss-of-function mutation 
impacts normal cellular mechanisms, are defined as tumor suppressor genes [1,7]. 
1.2.1. Oncogenes 
1.2.1.1. Discovery of Oncogenes 
Introduction 
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In the 1960s, it was realized that some animal cancers were caused by viruses. 
These observations led to the discovery of the first oncogene from the Rous Sarcoma 
Virus (RSV) called v-src (the viral oncogenes are called v-oncogenes) in 1970. Studies of 
RSV mutant revealed that RSV did not require v-src gene for its replication. Further 
studies showed that v-src was homologous to a host cellular gene (c-src) that was widely 
conserved in eukaryotic species. Studies of other transforming retroviruses from various 
species have led to the discovery of different retroviral oncogenes. The retroviral 
oncogenes are copies of normal cellular genes, the proto-oncogenes, that are captured 
from the genome of the host through a process known as retroviral transduction [7,8,9]. 
 
 
1.2.1.2. Function of Oncogenes 
 
Proto-oncogenes encode proteins that control cell proliferation, apoptosis or both. 
They can be activated to become oncogenes through alteration of the structure and/or 
amplification. The activated oncogenes which are capable of inducing neoplastic 
phenotypes in the cells, can be divided into six different groups based on the function and 
biochemical characteristics of protein products of their normal counterparts (proto-
oncogene): transcription factors, chromatin remodelers, growth factors, growth factor 
receptors, signal transducers, apoptosis regulators [7,10]. In section 1.4, I will discuss the 
oncogenic functions of transcription factors with the specific focus on the TALE family 
of homeodomain containing transcription factors. 
 
 
1.2.1.3. Oncogene Activation 
 
Oncogenes can be activated through genetic alterations of cellular proto-oncogenes, 
which involve a gain of function. This can be mediated through three different genetic 
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mechanisms in human neoplasms: (1) mutation, (2) gene amplification, and (3) 
chromosome rearrangements. All these changes lead to either a change in the structure of 
proto-oncogene or deregulation of its expression [7]. Different types of mutations, such as 
base substitutions, deletions, and insertions are able to activate proto-oncogenes through 
alterations in the structure of their encoded proteins. These alterations, which usually 
impact critical regulatory regions of a protein; enhance the transforming activity of the 
mutated protein [11]. For example, point mutations in key codons are frequently detected 
in the RAS family of proto-oncogenes. The mutated RAS encodes a protein that remains in 
the active state, which leads to continuous signal induction. The incessant signal 
transduction induces continuous cell growth [12]. 
Many cancer cells contain several copies of structurally normal oncogenes. The 
increased copy number of a gene due to genomic changes is called gene amplification. It 
was first discovered in some tumor cells, which acquire resistance to anti-growth 
treatments. The process of gene amplification, which takes place through redundant 
replication of genomic DNA, often creates chromosomal abnormalities called double-
minute chromosomes (DMs) and homogeneously staining regions (HSRs) [7,13,14]. The 
high frequency of DMs and HSRs in human tumors suggests that the amplification of 
specific proto-oncogenes may be a common occurrence in malignancies. Studies then 
showed that three proto-oncogene families including MYC, ERBB, and RAS are usually 
found amplified in a large number of human tumors [13]. 
Chromosomal rearrangements are more common in hematological malignancies 
than solid tumors. These cytogenetic abnormalities consist mainly of chromosomal 
translocations. Chromosomal rearrangements increase or deregulate transcription of the 
oncogenes by transcriptional activation of proto-oncogenes or the creation of fusion 
genes. For example, transcriptional activation occurs when a proto-oncogene is moved 
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next to an immunoglobulin or T-cell receptor gene. In this condition, regulatory elements 
of the immunoglobulin or T-cell receptor locus control the transcription of the proto-
oncogene [7]. The t(8;14)(q24;q32) translocation found in Burkitt lymphoma is one of the 
well studied examples of proto-oncogene activation. This chromosomal rearrangement 
brings the c-Myc gene under control of regulatory elements of the immunoglobulin heavy 
chain locus [15,16]. Gene fusions sometimes form chimeric transcription factors. For 
example, the E2A/PBX1 fusion protein found in childhood pre-B-cell ALL results from 
t(1;19)(q23;p13) translocation [16].   
 
 
1.2.2. Tumor-Suppressor genes 
 
The discovery of the oncogenes fueled the idea that different classes of genes must 
exist to carry out tumor-preventing functions. In fact, somatic cell fusion and 
chromosomal segregation experiments confirmed the existence of such genes involved in 
tumor suppression [17]. Over the years many such tumor suppressor genes have been 
identified based on the fact that only one single functional allele of the gene is sufficient 
to manifest cancer-preventing effects. These prototypic tumor suppressor genes are 
recessive and follow the “two-hit hypothesis” proposed by A.G.Knudson [18]. This 
hypothesis implies that biallelic gene inactivation is required before an effect is observed 
[18]. Further studies showed that not all tumor suppressor genes follow this hypothesis. 
Some tumor suppressors are haplo-insufficient for tumor progression; meaning that 
inactivation of a single tumor suppressor gene either by mutation, deletion or 
methylation-mediated transcriptional silencing provides a selective advantage during 
tumorigenesis. For example, inactivation of a single allele of the genes encoding Prep1, 
p53, TGF-β, 27kip1 and Dmp1 is sufficient to predispose mice to tumor development 
[19,20,21]. 
Introduction 
 
 
 17 
More than 30 tumor suppressors have been identified [22] that control a broad range 
of critical and highly conserved normal cellular activities including cell cycle checkpoint 
control, apoptosis, control of genomic integrity and repair of DNA damages, signal 
transduction, cell differentiation and adhesion, and angiogenesis. These functions can be 
deregulated in cancer cells [23]. Thus, tumor suppressor genes can be divided into 
gatekeepers, caretakers and landscapers based on their primary functions [24]. 
The “Gatekeeper” term was first proposed to explain the role of adenomatous 
polyposis coli tumor suppressor gene, which is consistently found mutated in colorectal 
tumorigenesis. Gatekeeper genes encode proteins that act directly to inhibit tumor growth 
by either suppressing proliferation, inducing apoptosis or promoting differentiation. 
Since, the loss of function of these genes is the rate-limiting event in tumorigenesis, the 
restoration of their function suppresses neoplasia. Each cell type has few gatekeepers, 
which are specific to the tissue in which they reside. Individuals with a hereditary 
mutation in one of two alleles of a gatekeeper gene are disposed to neoplasia [24,25]. 
“Caretaker” genes help to maintain genomic stability by encoding proteins that act 
in DNA repair and mitotic checkpoint pathways such as MLH1, BRCA1, MYH, and XPA. 
They indirectly suppress cell proliferation by ensuring the fidelity of DNA. Caretakers do 
not directly contribute to cancer development but their loss of function increases the DNA 
mutation rate, raising the probability that gatekeeper gene function will be lost. These 
alterations in caretaker genes will increase cancer development risk by 5 to 50 fold 
[24,25].   
The products of third class of tumor suppressor genes, the “landscapers”, act by 
modulating the microenvironment of the tumor cells. These genes regulate extracellular 
matrix proteins, cell surface receptors, adhesion proteins or secreted growth factors. Loss 
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of function mutations of landscapers generate aberrant microenvironment that prompts 
the neoplastic transformation of the adjacent epithelia [24,26]. 
 
1.3.  “ The Hallmarks of Cancer” 
 
12 years ago, Hanahan and Weinberg [2] enumerated six “Hallmarks of Cancer” 
which provided a logical framework to summarize and understand several decades of 
intense research dedicated to cancer. These six common traits (“Hallmarks”), which 
govern the transformation of normal cells to cancer cells, are essential for a cell to acquire 
a cancer phenotype by a multistep process. In 2011, they added two emerging hallmarks 
to this list due to the conceptual progress in the last decade. The complexity of the more 
than 100 different types of human cancers arises from disruption of the distinct regulatory 
circuits of the cells that govern normal cell proliferation and homeostatsis. Hanahan and 
Weinberg proposed that this complexity can be explained by a small number of traits that 
are common between most and perhaps all types of human tumors [2,27]. In the following 
sections these traits are discussed.  
  
1.3.1. Sustaining Proliferative Signals 
Tumors arise from unconstrained proliferation of cells harboring oncogenic 
activating or tumor suppressor inactivating mutations. Thus, uncontrolled proliferation is 
one of the fundamental features of cancer development. Normal cells require mitogenic 
growth signals to exit from a quiescent state and enter into active proliferation state. The 
growth-promoting signals released from a cell are transmitted through transmembrane 
receptors to its neighbors. Cell proliferation relies on the availability of growth promoting 
signals and normal cells stop proliferating in the absence of these signals. Cancer cells 
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develop a number of alternative ways to grow and proliferate independent of the absence 
of exogenous mitogenic signals [2,27]. Some cancer cells produce their own growth 
factors. The production of tumor growth factor α (TGFα) and platelet-derived growth 
factor (PDGF) by sarcomas and glioblastomas, respectively, are two representative 
examples [7]. They can also stimulate normal cells present in the tumor 
microenvironment to produce different growth factors [28]. The cell surface receptors that 
bind to the growth factors and transmit the growth signals inside the cell are often 
overexpressed in many cancer types. This elevation of the receptors makes cancer cells 
hypersensitive to a minimal amount of the growth factor which normally would not 
trigger proliferation [7]. For instance, the HER2/neu is overexpressed in stomach and 
mammary carcinomas [29]. Additionally, structural alterations of the receptor can also 
lead to ligand-independent signaling. Furthermore, growth factor autonomy may be 
achieved by constitutive activation of components of signaling pathways operating 
downstream of these receptors [30]. 
 
1.3.2. Evading Growth Suppressors 
 
Cells have evolved stringent mechanisms to control proliferation and tissue 
homeostasis via positively and negatively acting growth signals. Like the growth-
promoting signals, which were discussed in the previous section, the growth-inhibitory 
signals are transmitted through transmembrane cell surface receptors. These signals block 
proliferation either by transiently forcing cells out of the proliferative state into the 
quiescent state or by permanently preventing their proliferative ability by driving cells 
into a postmitotic state. The growth suppressor program is usually governed by tumor-
suppressors that act in different ways to inhibit cell growth and proliferation. The 
inactivation of these tumor suppressors conveys various capabilities to the cancer cells to 
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evade the anti-proliferative signals [2,27]. RB (retinoblastoma-associated) and p53 
proteins are the typical examples of the key tumor suppressors that control cell 
proliferation decision or activation of senescence and apoptosis programs. They are 
frequently inactivated in cancer by loss of function mutations [31,32,33].  
 
1.3.3. Resisting Cell Death 
Normal tissues maintain their homeostasis by balancing the rates of cell 
proliferation and cell death. Programmed cell death known as apoptosis plays a major role 
in maintaining cell population in the different tissues. Apoptosis can be triggered either 
by an extrinsic pathway mediated by cell surface death receptors bound by extracellular 
ligands, or by an intrinsic pathway mediated by mitochondria. The latter is triggered in 
response to different extracellular and intracellular stresses, such as growth factor 
depletion, hypoxia, DNA damage and oncogene induction. The ability of transformed 
cells to bypass the apoptotic barrier is widely implicated in the pathogenesis of cancer. 
Tumor cells develop different strategies to attenuate or escape apoptosis including the 
loss of p53 tumor suppressor, increasing expression of anti-apoptotic regulators and 
survival signals or down regulating the pro-apoptotic signals [27,34]. 
 
1.3.4. Enabling Replicative Immortality 
Normal cells have a finite replicative capability and are able to pass through certain 
and limited number of cell growth and division cycles. Mammalian cells in culture stop 
growing and go into senescence after 60-70 doublings. Some cells succeed to bypass this 
barrier and go into a crisis phase, which involves apoptosis and karyotypic abnormalities. 
Rarely, cells from a population in crisis acquire indefinite replicative potential. This 
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transition is called immortalization, which is one of the characteristics of the tumor cells 
[35]. In non-immortalized cells, the telomeres protecting the ends of chromosomes 
progressively shorten with each cell division, which leads to the end-to-end fusions of 
chromosomes, karyotypic disarray, crisis and cell death. Telomerase, which is responsible 
to maintain telomeric DNA is mainly absent in non-immortalized cells but is expressed at 
high level in a large majority of immortalized cells including human cancer cells [2,27]. 
 
1.3.5. Inducing Angiogenesis 
Inducing and sustaining of angiogenesis in tumors are crucial for their growth. In 
the adult angiogenesis is only transiently turned on in response to physiological processes 
such as wound healing. But during neoplastic growth an “angiogenic switch” is activated 
which remains on. This forces the normal quiescent vasculature to generate new vessels 
that helps to expand tumor growth by supplying nutrients and oxygen. The activation of 
the angiogenic switch is mediated by changing the balance of angiogenic inducers and 
inhibitors. For instance, vascular endothelial growth factor (VEGF) that induces 
angiogenesis is over expressed in tumors compared to their normal tissue counterparts. 
On the other hand, the angiogenic inhibitor thrombospondin-1, positively regulated by 
p53 tumor suppressor protein, is down regulated in tumors [2,27]. 
 
1.3.6. Activating Invasion and Metastasis 
Metastasis, the dissemination of cancer cells from their primary site to adjacent and 
distant organs, is the leading cause of death in patients with solid cancers. Invasion and 
metastasis are multistep process. This process begins with local invasion followed by 
intravasation of cancer cells in the nearby vessels and circulation of the cells through the 
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lymphatic and hematic systems. This process will end up with the extravasation of the 
cancer cells to the distant tissues and with the formation of micrometastatic lesions. At 
the molecular level, proteins involved in cell-to-cell and cell-to-matrix adhesion are 
important. E-cadherin, an important Ca(2+)-dependent cell-to-cell adhesion molecule, is a 
key suppressor of metastasis. This protein along with other adhesion molecules involved 
in cell-to-matrix adhesions is down regulated in cells possessing invasive or metastatic 
capabilities [2,27]. 
 
1.3.7. Reprogramming Energy Metabolism 
Under normoxic conditions, cells normally process glucose through glycolysis 
followed by oxidation of pyruvate in mitochondria. In anaerobic condition, however, 
glycolysis occurs in the cytosol and is followed by lactic acid fermentation. However, 
malignant cells usually limit their energy metabolisms mainly to glycolysis, even under 
normoxic conditions. This phenomenon is known as the Warburg-effect. There are 
several explanations for the Warburg-effect such as mitochondrial damage, adaptation to 
hypoxic environments, and shut down of mitochondria because of their involvement in 
apoptosis. Glycolysis provides most of the intermediates necessary for the production of 
nucleosides and amino acids, which facilitates biosynthesis of the macromolecules and 
organelles required for active cell proliferation. Therefore, Cancer cells often switch their 
metabolic pathways to anaerobic glycolysis to support the uncontrolled and continuous 
cell proliferation [27].  
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1.3.8. Evading Immune Destructions   
Multiple line of evidence point out that the immune system plays an important role 
in the recognition and eradication of malignant cells. The cancer immunosurveillance 
theory proposes that immune cells which constantly monitor cells and tissues, recognize 
and eliminate continuously arising, nascent transformed cells by immunoediting. 
Immunoediting is a process, which protects the individual from cancer growth and the 
development of tumor immunogenicity. It is composed of three major phases including, 
elimination, equilibrium, and escape. Although both innate and adaptive immune systems 
contribute significantly to immunosurveillance, many tumors manage to escape the 
immune barrier and drive immunological tolerance. This may lead to tumor progression 
by mimicking immune signaling pathways that impact the tumor microenvironment and 
activate immunosuppressive cells such as regulatory T (Treg) and myeloid-derived 
suppressor cells (MDSCs) [27]. 
 
1.4. Transcription Factors 
 
Transcription factors are sequence-specific DNA binding factors that regulate the 
transcription of target genes at the level of regulatory regions such as promoters or 
enhancers [36]. Most of the approximately 2600 proteins in the human genome that 
contain DNA-binding domains are thought to act as transcription factors. Therefore, 
almost 10% of the protein-coding genes in the human genome encode proteins that 
regulate transcription, which makes this family the single largest family of human 
proteins [37,38]. Multigene families of transcription factors share common DNA-binding 
domains such as zinc finger, leucine-zipper, helix-loop-helix and homeodomain motifs 
[39]. Transcription factors usually act in complex by binding to other proteins. They 
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operate as final link in the signal transduction pathway that translates cellular signals by 
alteration of gene expression [1]. 
Proto-oncogene transcription factors were discovered through their retroviral 
homologs. Chromosomal translocations often activate transcription factors in 
haematological and solid malignancies [40]. Examples of proto-oncogene transcription 
factors include Hoxa9, Meis1, Pbx1, erb A, ets, fos, jun, myb, and c-myc. For example, 
Hoxa9 transcription factor cooperates with Meis1 transcription factor in the induction of 
acute myeloid leukemias (AML) [41,42,43]. E2A-PBX1 chimeric protein which results 
from chromosomal translocation of the basic helix-loop-helix transcription factor E2A 
with the gene encoding the homeodomain protein PBX1 can cause pre-B cell acute 
lymphoblastic leukemias (ALL) [16]. 
 
1.4.1. Homeodomain Family of Transcriptional Regulators 
Homeobox was independently identified by two different groups in 1984 as a 
sequence motif shared between the Antennapedia and the Bithorax complexes, two 
homeotic loci in Drosophila. The mutations of these homeotic genes result in conversion 
of one body part to another [44,45]. Homeobox is an evolutionarily conserved 180-base-
pair sequence motif located in a large number of genes virtually in all eukaryotic species. 
The homeobox encodes a 60 amino acids DNA binding domain known as the 
homeodomain. The helix-turn-helix structure of the homeodomain is composed of three 
α-helices around a hydrophobic core that are essential in maintaining the structural 
integrity and in making essential contacts with DNA (Figure 1.2). Homeobox genes play 
critical roles in different cellular processes, including body plan specification, pattern 
formation, and cell fate determination during development [46,47]. These “master 
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regulators” of development also control various cellular processes including proliferation, 
differentiation, apoptosis, cell shape, cell adhesion and migration [48]. 
 
Figure 1.2. Homeodomain-DNA complex [49]. To form this complex the N-terminal 
tail of helix 1 inserts into the minor groove of DNA and helix 3 lies in the major groove.  
 
The high number of homeodomain containing genes sometimes cause difficulty in 
their classification. In the human genome at least 200 homeobox genes have been 
estimated [50]. These genes are divided into nine superfamilies on the basis of the level of 
similarity among their respective homeodomains. These superfamilies include the ANTP 
(including the HOX and NKL families), PRD (including the PAX family), POU, HNF, 
LIM, SINE, CUT, ZF, PROS and TALE groups (Figure 1.3) [50] . 
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Figure 1.3. Phylogenic tree of human homeodomain proteins excluding ANTP and 
PRD classes is constructed using maximum likelihood method [50]. 
 
 
1.5. HOX Genes and Their Role in Cancer 
In contrast to most homeobox genes, which are dispersed throughout the genome, 
HOX genes are organized in chromosome clusters. In man, 39 HOX genes are organized 
in 4 clusters (A-D). They are expressed in an orderly manner corresponding to their 
positions from the 3ʹ′ to the 5ʹ′, within each cluster. HOX genes function to pattern the 
anterior-posterior body axis of embryos. They are also involved in various processes 
including limb bud axis patterning, hematopoiesis, organogenesis, apoptosis, receptor 
signaling, differentiation, motility, and angiogenesis [51,52]. 
The homeobox motif of HOX genes is located in exon 2, placing the homeodomain 
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in the C-terminal half of the protein. In addition to the homeodomain, HOX proteins 
contain a short conserved tryptophan-containing hexapeptide motif (HP) that is required 
to mediate specific interactions with the TALE motif (Three Amino acid Loop Extension) 
of PBX homeodomain proteins [53]. HOX proteins can regulate the transcription of 
downstream targets by acting as monomers, homodimers or heterodimers with the TALE 
family of cofactors or with the non-homeodomain proteins such as CBP and SMAD [52].  
This subgroup of the homeobox superfamily not only is crucially important in 
developmental regulation, but also is implicated in a growing number of diseases, 
including cancer. Aberrant expression of HOX genes has been described in many solid 
tumors and leukemias. The deregulated expression of HOX genes perturbs the fine 
balance between cell proliferation and differentiation that is essential for the normal 
development and differentiation. Different mechanisms can alter this balance leading to 
malignancies. The first mechanism is “temporospatial deregulation”. In this case the 
expression pattern of HOX genes in tumors arising from a specific tissue temporospatially 
differs from that in normal tissue [49,52]. For instance, the expression levels of all HOX 
genes in 48 primary esophageal squamous cell carcinoma (ESCC) and 7 normal 
esophagus specimens were quantified by qRT-PCR. The results showed that in normal 
esophagus more 3ʹ′ HOX genes are expressed compared to the 5ʹ′ genes. However, in 
tumor samples the expression of 5ʹ′ HOX genes was significantly increased [54]. The 
second is “gene dominance”, in which HOX genes are overexpressed in tumors compared 
to the normal tissues [49,52]. HOXA9 is overexpressed in acute myeloid leukemia (AML) 
that is correlated with poor prognosis and treatment failure in AML patients [55]. 
Moreover, the chromosomal translocation between HOXA9 and other HOX genes with the 
nucleoporin protein NUP98 leads to the formation of fusion proteins, which inhibit 
differentiation and induce transformation of hematopoietic progenitor cells [56,57,58]. 
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The last mechanism is “epigenetic deregulation” in which HOX genes are aberrantly 
silenced or downregulated due to promoter methylation in the tissues in which they are 
normally expressed [49,52].  
The perturbation of normal HOX gene expression affects different pathways that 
induce tumorigenesis. Some result in the maintenance of more embryonic state through 
the suppression of differentiation or activation of anti-apoptotic pathways. For instance, 
HOXC8 overexpression in prostate cancer specimens correlates with loss of 
differentiation and androgen-independent proliferation [59,60]. Downregulation of 
HOXA5 and HOXA10 perturbs the balance between apoptosis and proliferation. In this 
case, downregulation of these genes leads to the suppression of p53 expression and 
therefore to the block of apoptosis in a breast cancer cell line [61,62]. In some tumors 
altered receptor signaling pathways due to the deregulation of HOX genes drives tumor 
growth. For example in ovarian and breast cancer HOXB13 exerts oncogenic activity by 
ER upregulation and tamoxifen resistance [63]. The involvement of HOX gene in the 
pathogenesis of different cancer has been summarized in table 1.1 [52]. 
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Table 1.1. Overview of HOX genes dysregulation in tumorigenesis [52] 
 
 
1.6. The TALE Family of Homeobox Genes 
TALE superclass of homeodomain proteins is characterized by a divergent 
homeodomain harboring three extra amino acids in the loop between helix 1 and helix 2 
of the DNA binding domain. This loop is crucial for the interaction with other 
homeodomain proteins [64]. This family forms an ancient subclass within the 
homeodomain transcription factors and plays crucial roles in the development of animal, 
plant, and fungi [64].  
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1.6.1. Classification 
The TALE superclass of transcription factors is divided into five classes of genes in 
animals (PBC, MEIS, TGIF, IRQ and MKX), two in fungi (M-ATYP and CUP) and two in 
plants (KNOX and BEL) [64,65]. The PBC class in animals includes PBX1, 2, 3 and 4 in 
mammals, Extradenticle (ExD) in Drosophila and Ceh-20 in C. elegans. The MEIS class 
is subdivided into two sub-families; the MEIS sub-family itself includes MEIS1, 2, 3 in 
mammals, Homothorax (Hth) in Drosophila and unc-62 (ceh-25) in C. elegans. The 
PREP sub-family includes PREP1/PKNOX1 and PREP2/PKNOX2 in mammals and psa3 
in C. elegans. There is no PREP1 homolog in Drosophila but in other insects such as the 
malaria mosquito, the honeybee, and the red flower beetle there is both a MEIS and a 
PREP Homolog [64]. 
 
1.6.2. Evolution and Structure of PBX, MEIS, and PREP genes 
In addition to the TALE homeodomain, there is another domain upstream of the 
TALE homeodomain that is conserved between animal MEIS genes and plant KNOX 
genes, which is called MEINOX [64,65]. A similar MEINOX domain is also present 
within the PBC domain of PBC class genes [66]. The significant sequence similarity 
between MEIS and KNOX and PBC domains indicates that they are derived from an 
ancient MEINOX domain already present when plants and animal diverged (Figure 1.3). 
The MEINOX domain is split into two subdomains, joined by a flexible linker. Secondary 
structure predictions suggest that the MEINOX domain is constituted of α helical 
structures [64]. However, no structural study is available. The PBX MEINOX domain is 
composed of two motifs, PBC-A and PBC-B, which together are known as the PBC 
domain. There is a third conserved motif downstream of the homeodomain that is called 
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PBC-C composed of 15 conserved residues which is essential for the interaction with 
HOX proteins on DNA (Figure 1.4) [64].  
The MEINOX domain of MEIS and PREP proteins is also split into two motifs 
called HR1 (Homology Region 1) and HR2 or MEIS A and MEIS B motifs (together 
known as MEIS domain).  The MEIS A motif of PREP genes is shorter than in MEIS. In 
addition, other structural differences between MEIS and PREP genes arise from three 
other motifs (MEIS C, MEIS D and MEIS N) present only in MEIS (Figure 1.4) [64].  
The Prep1 homeodomain sequence has 44/60 (70% identity) identity and 54/60 
(86% similarity) similarity to Meis1. However, Pbx1 homeodomain has 22/60 (35% 
identity) identical and 41/60 (65% similarity) similar residues with Prep1. Although 
Prep1 and Meis1 are highly homologous all over the homeodomain, this homology is 
mainly concentrated (16/18 residues) in the third helix (the DNA recognition helix). In 
addition to the homeodomain, Prep1 and Meis1 display strong homology over the HR1 
and HR2 regions. Moreover, the position of HR1 and HR2 relative to the homeodomain is 
conserved between Prep1 and Meis1 proteins. Beside the homeodomain and HR1 and 
HR2 domains, these two proteins do not share high sequence similarity [67]. 
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Figure 1.4. Evolutionary relationship between Pbx, Meis and Prep genes. Adapted 
from [64]. 
 
1.6.3. The Pbx Interaction with Meis/Prep Regulates their Sub-Cellular 
Localization. 
The regulation of transcription factor activity plays an important role in various 
biological processes. Different mechanisms regulate the transcription factor activity such 
as post-translational modifications, expression level and protein stability. In addition, 
since a transcription factor exerts its transcriptional regulation role in the nucleus, the 
control of its nuclear localization plays a crucial role in this regulation [68]. Therefore the 
presence of Pbx1, Meis1 and Prep1 transcription factors in the nucleus of cells is 
determinant for the regulation of the appropriate target genes. Numerous studies have 
shown that Pbx1 nuclear/cytoplasmic distribution is tightly regulated through different 
mechanisms [69]. Now, I will focus on the role of Meis/Prep and Pbx interactions on their 
nuclear translocation (Figure 1.5). For this interaction, the PBC-A domain of Pbx1 
[70,71] and the HR1 and HR2 domains of Meis1/Prep1 [67,71] are required. The LFPLL 
motif in HR1 is essential for Pbx1 binding [72]. Pbx1 and Meis1/Prep1 bind 
cooperatively to DNA, although they interact efficiently in the absence of DNA as well 
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[70,71,73]. Their interaction in the absence of DNA regulates the subcellular localization 
[74,75] and stability [74,76] of Pbx proteins. 
Pbx1 has a dynamic subcellular localization. It contains two cooperative NLS 
(nuclear localization signal) [77] and two independent NES (nuclear export signal) [78].  
The first NLS is located in the N-terminal arm of the HD (amino acids 234-239) and 
contains the consensus RRKRR sequence. The second, less conserved (KRIRYKKNI), is 
located in helix 3 (amino acids: 285–294) [77]. The two NES are located within the PBC-
A domain spanning amino acids 45-72 and 73-90 respectively [78]. The two NES can 
mask and inhibit the NLS by an intramolecular interaction between the N-terminus and 
homeodomain of Pbx1. The conformational change of Pbx1 due to the interaction with 
Meis/Prep exposes the Pbx1 NLS, which causes their (Meis/Prep in complex with Pbx1) 
nuclear translocation [77]. The NES of Pbx1 mediates interaction with the nuclear export 
receptor Crm1 that exports Pbx from the nucleus. Interestingly, the two NESs are located 
within the domains required for the interaction with Meis/Prep and deletion of either of 
the two NESs impairs this interaction. Since the contact domain for Crm1 and Meis/Prep 
overlap, therefore the interaction of Pbx1 with Meis/Prep masks the NESs and allows 
Pbx-Meis/Prep to stay in the nucleus as heterodimers [68,75,78]. Pbx1 nuclear 
localization is not only dependent on the Meis/Prep interaction but there are other 
mechanisms, which regulate its subcellular distribution. However, Prep1 does not have its 
own NLS and mainly relies on Pbx-Prep interaction for its nuclear translocation [75]. 
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Figure 1.5. Pbx1 and Prep1 interaction and subsequent translocation to the nucleus. 
Pbx also interacts with Meis through the same domain and the subsequent complex 
translocates to the nucleus as shown in this figure. Adapted from [68,75,78]. 
 
1.6.4. The PBC Family in Mammals 
 The PBC family contains four members in mammals; PBX1, PBX2, PBX3, and 
PBX4. PBX1 (Pre-B cell leukemia homeobox 1) was initially identified as E2A-Pbx1 
oncogenic fusion protein resulting from chromosomal translocation t(1;9) in human pre-B 
cell acute lymphoblastic leukemia (ALL) [79,80]. PBX2 and PBX3 were identified based 
on their extensive homology to PBX1. Overall, PBX2 and PBX3 proteins have 92 and 
94% identity to PBX1 over the 266 amino acids within and flanking their homeodomain. 
But they have significant differences in amino acid composition close to their amino and 
carboxy termini [81]. PBX1 and PBX3, and not PBX2, have two isoforms with different 
carboxy termini due to alternative splicing: PBX1a, PBX1b and PBX3a, PBX3b [51,81]. 
PBX2 and PBX3 are expressed in embryonic and adult tissues as well as different cell 
lines and their expression is not restricted to the specific stage of the embryo 
development. However, PBX1 is not expressed in lymphoid cell lines [81]. Also different 
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isoforms of PBX1 show different expression patterns. For example, Pbx1a expression is 
restricted to neural tissues while Pbx1b exhibits widespread expression patterns in the 
mouse embryo [51]. Finally, the fourth mammalian PBX family member, Pbx4, is only 
expressed in testis, especially in spermatocytes in the pachytene stage of the first meiotic 
prophase [82]. The PBX genes are not clustered and map to different chromosomes: PBX1 
is mapped to the first chromosome in mouse and man, PBX2 to chromosome 17 in mouse 
and 6 in man, PBX3 to chromosome 2 in mouse and 9 in man [81], PBX4 to chromosome 
8 in mouse and 19 in man [82].  
Since PBX genes show extensive sequence identity, their functional differences are 
not due to their biochemical functions but more likely to their different expression 
patterns [83]. For example the different PBX proteins show very similar DNA binding 
properties in in vitro assays [84]. Thus, PBX proteins might have at least partially 
redundant functions where their expression overlap. In general Pbx proteins are involved 
in diverse developmental processes. For instance Pbx1 is implicated in hematopoiesis, 
skeleton patterning, pancreas, and urogenital systems organogenesis [85,86,87]. 
 
1.6.4.1. Pbx Proteins as Hox Cofactors 
Pbx proteins interact with Hox proteins from paralogue groups 1 to 10 to increase 
their DNA affinity and specificity [88]. This interaction is mediated by the binding of the 
Hox hexapeptide motif located in the N-terminal arm of the homeodomain to a 
hydrophobic pocket formed between the three amino acid loop extension and helix 3 of 
the Pbx homeodomain. This interaction is DNA-dependent [89]. Also the PBC-C domain 
of Pbx has been shown to be involved in Hox-DNA complex formation [64]. 
The identification of Hox/Pbx regulatory elements in the promoters of mammalian 
Hox genes was the first evidence that Pbx proteins function as Hox cofactors. This 
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regulatory element consists of paired Hox/Pbx binding sites and mutating either the Hox 
or the Pbx binding sequence abolishes its function [90,91]. The second piece of evidence 
came from the Pbx loss of function mice. Pbx1 and Pbx3 mutant mice are reminiscent of 
late stage Hox loss-of-function phenotype. Pbx1 deficient mice develop normally till 
E11.5. But later display severe organ hypoplasia (lungs, liver, stomach), ectopia (thymus 
and kidneys) or aplasia (spleen), which lead to the death of the embryos at E15.5 [86]. 
For example, impaired hematopoiesis in Pbx1-/- embryos [92] resembles the Hoxa9-/- 
mutant phenotype [93] and the cervical vertebral malformations of Pbx1-/- embryos [86] 
recapitulate Hoxa3-/- and Hoxd3-/- loss-of-function phenotypes [94]. Pbx3-/- mutants die 
within few hours after birth due to central respiratory failure resulting from abnormal 
activity of inspiratory neurons in the medulla where this gene is highly expressed [95]. 
The congenital apnea phenotype seen in Pbx3-/- mice resembles Rnx-/- mutants phenotype. 
Pbx2-/- mice are instead viable and do not show obvious phenotypic anomalies [96]. This 
suggests that another member of PBC family compensates for the loss of Pbx2 as 
observed by the phenotype of the double mutants [51]. 
In vivo observations, such as genetic interaction between Pbx1 and Hoxa2 to 
pattern branchial arch 2-derived craniofacial structures, suggest that Hox proteins act 
together with Pbx proteins to regulate developmental processes [51]. Finally Pbx presence 
is essential for Hox activity. For example anterior hox genes overexpression in zebrafish 
leads to a posterior transformation of segment identities in the hindbrain in Pbx wild-type 
background, but in the pbx4 mutants this effect is strongly suppressed [97]. 
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1.6.4.2. Hox-independent Functions of Pbx Proteins 
A growing body of evidence suggests that Pbx proteins may act broadly to 
modulate non-Hox proteins and non-homeodomain proteins functions and indeed 12% of 
Pbx1 putative partners are non-homeodomain transcription factors [69]. In vitro studies of 
muscle differentiation have shown that Pbx1-Meis complexes are constitutively bound to 
the myogenin gene marking the region where MyoD will be recruited. MyoD indirect 
promoter interaction through Pbx1, recruits the chromatin-remodeling SWI/SNF enzymes 
of the chromatin-remodeling complex. This facilitates the binding of other regulators, 
which finally leads to transcriptional activation of the myogenin gene. These findings 
suggest a critical role of Pbx1 in marking specific genes for activation [98].  Furthermore, 
Pbx1 and Prep1 proteins bind to the FSHβ (Follicle-stimulating Hormone) promoter and 
recruit Smad proteins regulating FSHβ gene response to activin. This study highlights the 
link between Pbx and TGFβ signaling [99]. 
 
1.6.4.3. PBX Proteins in Cancer 
Pbx genes are normally involved in developmental processes and cell fate 
determination during organogenesis. However, the accumulating evidence shows that 
they are also involved in the development of human cancers [16,92,100]. Pbx1 has been 
implicated as a proto-oncogene in human leukemia. The t(1;19) chromosomal 
translocation detected in almost 23% of all pediatric pre-B cell ALL patients forms an 
oncogenic fusion protein, so called E2A-PBX1, which correlates with poor response to 
standard chemotherapeutic protocols [101]. In the resulting fusion protein, the DNA 
binding domain of E2A is replaced by the DNA binding domain of PBX1. So, the E2A-
PBX1 fusion protein contain the E2A activation domain and the homeodomain of PBX1 
Introduction 
 
 
 38 
[16]. Two alternatively spliced isoforms of PBX1 are detected as a fusion protein with 
E2A, E2A-PBX1a and E2A-PBX1b in human primary tumor cells [79]. 
E2A belongs to the class I family of basic helix-loop-helix (bHLH) proteins and 
contains two activation domains called AD1 and AD2. The B cell development blockage 
at the early pro-B cell stage in E2A-deficient mice points out the importance of E2A as a 
B lymphopoiesis regulator [102]. It also carries out various functions from regulation of 
Ig class switch recombination in peripheral mature B cells [103] to T cell development 
[104]. Although the underlying mechanisms by which E2A-PBX1 causes pre-B cell ALL 
are not clear so far, the main contributions of this oncoprotein to the pathogenesis of ALL 
are summarized in this section. E2A can act as a tumor suppressor to suppress the 
tumorigenic cell growth both in vitro and in vivo [16]. The t(1;19) chromosomal 
translocation disrupts one allele of both E2A and PBX1. This may lead to a decrease in 
the amount of functional E2A acting as a tumor suppressor. On the other hand the 
cooperation of the E2A activation domain with the DNA binding domain of PBX1 
activates transcription through PBX1 binding sites [105] which can alter the regulation of 
HOX/PBX target genes. These alterations seem to be oncogenic. For instance, E2a-Pbx1a 
can collaborate with Hoxa9 to cause AML [106]. PBX1 binding to MEIS/PREP proteins 
is one of the mechanisms that regulate its nuclear-cytoplasmic localization (reviewed in 
section 1.6.3). But in the fusion form the MEIS/PREP interaction domain of PBX1 (PBC-
A and PBC-B domains) is disrupted which leads to the constitutive presence of the fusion 
protein in the nucleus. Hence the E2A-PBX1 protein is always available for dimerization 
with HOX proteins [16,107]. A screening to identify other factors involved in E2A-
PBX1-induced transformation revealed that Pim1 and NotchΔC enhance E2A-PBX1 
tumorigenicity [16,108].  
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In addition to the role of Pbx1 in leukemogenesis, it also has been implicated in the 
pathogenesis of different human solid cancers including breast, ovarian and prostate 
cancers [85,100,109]. Two-thirds of all breast cancers are estrogen receptor alpha (ERα) 
dependent. Following estrogen stimulation, ERα binds to DNA and promotes a pro-
tumorigenic transcriptional response. PBX1 acts as a pioneer factor in ERα positive breast 
cancer. It opens the chromatin by recognizing and binding to the chromatin harboring the 
H3K4me2 epigenetic modification, which leads to chromatin remodeling and the 
recruitment of ERα [85].  
In the pathogenesis of ovarian cancer not only the highly deregulated expression of 
HOX genes is important, but also the PBX1-HOX heterodimer complex contributes to the 
oncogenic activity in this cancer. The disruption of the interaction between HOX proteins 
and PBX1 induces apoptosis in the ovarian cancer derived line SK-OV3, and significantly 
reduces tumor growth in vivo [110]. Functional inactivation of NOTCH3 that is amplified 
in ovarian cancer identified PBX1 as a downstream effector of the Notch signaling 
pathway. This finding suggests that NOTCH3 activation and the subsequent activation of 
PBX1 potentially modulates the function of HOX proteins, which are deregulated in 
ovarian cancer [100]. However the molecular mechanism of how PBX1 promotes 
tumorigenesis remains unclear. An integrated approach overlapping PBX1 ChIP-chip 
with the PBX1-regulated transcriptome in ovarian cancer cells has identified the genes 
whose transcription is directly regulated by PBX1. Among these target genes, a 
homeodomain protein, MEOX1, was identified and its interaction with PBX1 
demonstrated. The suppression of MEOX1 caused a similar growth inhibitory phenotype 
similar to PBX1 inhibition and its ectopic expression functionally rescued the PBX1-
deficient effect, suggesting that MEOX1 mediates the cellular growth signal of PBX1. 
This study also revealed potential cis-regulatory cofactors of PBX1, which include 
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GATA1, FOSL1, MEIS1, JUNB, and a ‘‘TAATTA’’ motif for MEOX1 and HOX. The 
motifs of these transcription cofactors were significantly enriched in PBX1-bound 
sequences, suggesting that these proteins may work in concert with PBX1 to facilitate 
transcriptional regulation [111]. 
The role of other PBX proteins in human cancers remains mysterious and needs to 
be studied. There is only one recent study that showed the correlation of high level PBX2 
expression with a poor prognosis in gengival squamous cell carcinoma [112]. Another 
recent study showed the upregulation of PBX3 in prostate cancer and its post-
transcriptional regulation by androgen through Let-7d [113]. 
 
1.6.5. The MEIS Family  
 
The MEIS or MEINOX family in mammals is divided into two subclasses, MEIS 
and PREP. MEIS subclass is composed of MEIS1, MEIS2 and MEIS3 [114,115,116]. 
PREP subclass has two paralogs in man, PREP1 and PREP2, with 60% sequence identity 
[67,117,118]. MEIS1 is mapped to chromosome 11 in mouse and 2 in man. MEIS2 is 
located on the chromosome 2 in mouse and 15 in man. MEIS3 is on the chromosome 7 in 
mouse and 19 in man. PREP1 is located on the chromosome 17 in mouse and 21 in man 
and PREP2 is mapped on chromosome 9 in mouse and 11 in man. The Drosophila 
ortholog of MEIS1 is called homothorax (hth). HTH is required for the nuclear 
localization of EXD, the PBX ortholog in Drosophila. HTH and EXD have many 
functions in Drosophila including the regulation of eye development, patterning the 
embryonic peripheral nervous system and proximal-distal limb development [119].  
Like Pbx, Meis/Prep proteins are also well known as Hox cofactors. They are 
required for the normal function of the Hox-Pbx complex. Their interaction with Hox-Pbx 
complex increases Hox DNA binding specificity (Hox-Pbx binding sites occur once every 
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8200 bp and Hox-Pbx-Meis/Prep once every 420000 bp [69]) [51]. The tripartite Hox-
Pbx-Meis/Prep complex is formed by the interaction of HR1 of either Meis or Prep with 
PBC-A of Pbx. The subsequent complex can form a ternary complex through the 
Homeodomain of Pbx bound to the hexapeptide motif of Hox [71,73,120]. The consensus 
Hox/Pbx binding site, ATGATTGATGA, is often associated with essential binding sites 
for the Meis/Prep proteins [51,120]. Trimeric Hox-Pbx-Meis/Prep complexes were shown 
to be crucial in the early development of the vertebrate hindbrain. For instance Prep1, 
Pbx1 and Hoxb1 form a ternary complex on the rhomobomere 4 enhancer of the Hoxb2 
gene [90,121]. In the following sections the different biological functions of Meis/Prep 
proteins, especially their role in tumorigenicity will be reviewed in detail. 
 
1.6.6. The Meis Subclass Discovery and Mutant Phenotypes 
 
Meis1 (Myeloid Ecotropic viral Integration Site 1) was isolated as a site of viral 
integration in 15% of the leukemias arising in BXH-2 mice. It is located on proximal 
mouse chromosome 11 and human chromosome 2p23-p12, in a region known to contain 
translocations found in human leukemias. Meis1 has two alternatively spliced isoforms in 
mammals: Meis1a and Meis1b [114,115]. Meis2 and Meis3 were identified by DNA 
cross-hybridization with a Meis1 probe under low stringency conditions [116]. A screen 
for genes involved in retinoic acid differentiation in P19 embryonic carcinoma cells also 
led to the isolation of Meis2 [122]. 
Meis1-/- embryos die around E14.5. They exhibit a variety of malformations 
including severe hemorrhage because of the lack of well-formed capillaries, although the 
larger blood vessels are normal, anemia, liver hypoplasia, the complete absence of 
megakaryocytes, decreased number of hematopoietic stem cells and eye defects (Figure 
1.6) [119,123]. Meis1 is strongly expressed in hematopoietic stem cells and is essential 
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for the proliferation and self-renewal of these cells. Meis2 seems to be involved in the 
control of chick limb outgrowth [124,125]. No Meis2 and Meis3 KO mice have been 
described. 
In the mouse embryo, Meis1 and Meis2 show region-specific expression patterns 
from E10.5 until birth, defining distinct sub territories in the developing telencephalon. 
Meis genes are highly expressed in the subventricular zone and mantle regions of the 
ventral telencephalon [126]. Meis1 is required for the regulation of Pax6 expression 
during vertebrate lens development [127]. Moreover Meis genes are involved in 
patterning of the hindbrain [128,129]. In general, Meis1 and Meis2 are expressed in the 
following tissues: hematopoietic, central nervous system (CNS), liver and pancreas, 
gastrointestinal tract, respiratory (lung), cardiovascular, female tissue, male tissue, urinary 
tract (kidney), skin and soft tissues [130] [131]. 
 
 
Figure 1.6. Morphology of Meis1-deficent embryo compared to the wild-type at 
E13.5 [119]. 
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1.6.7. Meis proteins in cancer 
1.6.7.1. Role of Meis1 in leukemogenesis 
An oncogenic collaboration between Hox and Meis proteins has been established 
both by proviral insertion [116] and by retroviral overexpression studies [41]. Retroviral 
insertions induce myeloid leukemia in BXH-2 mice by deregulating the expression of 
proto-oncogenes and tumor suppressor genes. Proviral tagging was used to identify 
common viral integration sites in the leukemias derived from BXH-2 mice. This led to the 
identification of Hoxa7, Hoxa9 and Meis1 genes whose expression was activated by 
proviral integration. Strong correlation between proviral activation of Hoxa7 and Hoxa9 
with proviral activation of Meis1 implies that Hoxa7 and Hoxa9 cooperate with Meis1 in 
leukemogenesis [115,116]. Indeed, overexpression of Hoxa9, Meis1 or Pbx1 per se, is not 
sufficient to efficiently transform murine primary bone marrow cells. Furthermore, Meis1 
overexpression in hematopoietic progenitors not only does not immortalize these cells but 
also induces apoptosis, which is caspase-dependent, and can be abrogated by Hoxa9 
coexpression [132]. 
 Although Hoxa9 overexpression induces leukemia after long latency [43], 
overexpression of Meis1, but not Pbx1 [41] or Prep1 [43], drastically lowers the latency 
of Hoxa9-induced AML. Thus Hoxa9 selectively cooperates with Meis1 in leukemic 
transformation in mice and human AML. Hoxa9 and Meis1 are expressed in more than 
80% of human AML [133] and their expression levels are correlated with poor prognosis 
in AML [134]. 
Although Meis1 and Prep1 can interact with Pbx and Hox family members, they 
play opposite roles in tumorigenesis. In fact, Prep1 overexpression is not capable of 
accelerating Hox-induced leukemia. Indeed, in agreement with its tumor suppressor 
function [19], Prep1 marginally increases the latency of leukemia formation [43].  
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 Molecular dissection of Meis1 showed that three different domains of Meis1 
including the Pbx-interacting domain, the DNA binding homeodomain and the C-terminal 
domain (CTD), are required for its oncogenic activity [42,135,136]. In agreement with 
these data, chimeric Prep1 carrying the C-terminal domain  (the transactivating domain) 
of Meis1 acts as a Hoxa9-collaborating oncogene and accelerates the onset of Hoxa9-
induced leukemia by regulating expression of genes involved in chromatin accessibility 
and cell cycle progression. So, chimeric Prep1 is capable of inducing a distinct gene 
expression profile that is associated with wild-type Meis1 overexpression [137]. 
Meis1 fusion to Vp-16 trans-activating domain (Vp16-Meis1) forms a chimeric 
oncoprotein, which induces leukemia in the absence of coexpressed Hox genes. Vp16-
Meis1 induced leukemias exhibit longer latency than observed with Hoxa9-Meis1 
coexpression. Vp16-Meis1-induced transformation requires the Pbx and DNA binding 
domains of Meis1. The CTD of Meis1 and the N-terminal domain (NTD) of Hoxa9, 
which is required to cooperate with wild-type Meis1, are dispensable in Vp16-Meis1 
mediated transformation. The fact that the Vp16 domain replaces the function mediated 
by the Meis1 CTD and the Hoxa9 NTD, suggests that the Meis1 CTD and the Hoxa9 
NTD might recruit cofactors containing HAT activity. Thus, Meis1-Pbx, Hox-Pbx and 
Meis1-Hox-Pbx complexes co-occupy the promoters of leukemia-associated genes using 
the Meis1 CTD and the Hoxa9 NTD for transcription activation [138]. 
Characterization of leukemic cells overexpressing Hoxa9 and Meis1 revealed that 
they are poorly differentiated myeloid lineage cells. Since hematopoietic stem cells 
(HSC) have both myeloid and lymphoid potential [41], the myeloid feature of Hoxa9-
Meis1-induced leukemia suggests that HSCs are not the target of HoxA9-Meis1 
transformation.  
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Study of the mechanisms underlying Hoxa9 and Meis1 cooperation showed that 
Meis1 suppresses myeloid differentiation pathways that are not altered by Hoxa9. 
Constitutive expression of Hoxa9 immortalized bone marrow cells by blocking the 
macrophage and neutrophil differentiation of primary myeloid progenitors cultured in 
granulocyte-macrophage colony-stimulating factor (GM-CSF). However, the monocyte 
differentiation in response to macrophage CSF (M-CSF) and granulocytic differentiation 
in response to granulocyte CSF (G-CSF) were not impaired. In Hoxa9-immortalized 
progenitors, Meis1 suppresses differentiation in response to G-CSF and promotes self-
renewal [139]. Therefore complementary differentiation pathways targeted by Hoxa9 and 
Meis1 regulate progenitor abundance by blocking differentiation and promoting self-
renewal in response to the different subsets of cytokines during myelopoiesis. Moreover, 
Meis1 up-regulates Pbx2 by 3-fold in AML cells and prevents transcription of genes 
which are normally activated in neutrophil differentiation such as Egr-1, neutrophil 
gelatinase B and CD14 [139]. 
The other mechanisms by which Meis1 cooperates with Hoxa9 to induce AML are 
regulated through Meis1-Pbx complexes. These mechanisms include increased expression 
of Flt3 (Fms-like tyrosine kinase 3) proto-oncogene, a receptor for FL (Flt3 ligand), and 
other genes involved in short-term HSCs (ST-HSCs), such as Cd34 and Sox4 proleukemic 
transcription factor [140]. It has also been shown that both Meis1 and Hoxa9 bind to the 
Flt3 promoter. Flt3 expression is associated with ST-HSCs and Flt3-deficient stem cells 
are impaired in lymphoid and myeloid reconstitution potential [141]. However, Flt3-
deficient hematopoietic cells are efficiently transformed by Hoxa9-Meis1 coexpression, 
suggesting that Flt3 is not the only essential mediator of leukemogenesis and therefore 
other genes must be involved in leukemic transformation [142].  
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Trib1 and Evi1 have been identified as putative cooperative genes located close to 
the common retroviral integration sites in Hoxa9-Meis1 induced AML and their 
overexpression accelerates AML formation through cooperation with Hoxa9 and Meis1. 
One possible model for this interaction is the involvement of the Flt3/MAPK pathway, 
which is important in leukemogenesis. On one hand, Meis1-mediated Flt3 upregulation 
leads to MAPK phosphorylation. On the other hand Trib1 interaction with MAPKKs 
enhances MAPK phosphorylation. The consequence of these phosphorylations force the 
MAPK signaling leading to leukemia [143]. 
 In search of other Hoxa9-Meis1 target genes involved in leukemogenesis and to 
shed more light in the field, the c-Myb proto-oncogene was found to be essential but not 
sufficient for the transformation [144]. c-Myb is a key regulator of normal hematopoiesis 
which is frequently altered in lymphomas and leukemias. The mechanisms underlying 
this alteration are poorly documented. One recent study showed the role of Hoxa9 and 
Meis1 in c-Myb gene regulation in AML. Hoxa9 and its cofactors Meis1, Pbx1 and Pbx2 
directly regulate the expression of the c-Myb gene by binding to the c-Myb locus on 
consensus HoxA-TALE sequences in normal and Hoxa9-Meis1 transformed 
hematopoietic cells [145]. 
The identification of different Meis1 target genes such as Flt3, Cd34, Erg1, c-Myb, 
and Trib2 suggests that Meis1 functions to modulate multiple pathways in 
leukemogenesis. In this regard, cell-cycle analysis using the M33-Meis1 fusion, which 
suppresses the upregulated Meis1 target genes in normal and malignant hematopoiesis, 
revealed that Meis1 induces proliferation of normal and malignant HSCs by modulating 
G-1 phase regulators. In fact, Meis1 promotes G1-to-S phase progression by direct 
transcriptional regulation of cyclin D3 and subsequent hyperphosphorylation of 
Retinoblastoma (pRb) [135]. 
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Hoxa9 and Meis1 are reported overexpressed not only in human AML [133] but 
also in acute lymphoid leukemia (ALLs) harboring MLL (mixed lineage leukemia) 
chromosomal translocations [146]. In hematopoiesis, MLL regulates Hox gene expression 
by methylation of histone H3 at lysine 4 through its intrinsic histone methyltransferase 
activity [146]. The constitutive expression of Hoxa9 and Meis1 in immortalized myeloid 
progenitors by MLL fusion oncoproteins such as MLL-ENL suggests that Hoxa9 and 
Meis1 are crucial targets for MLL-ENL-induced cellular transformation [147]. Since 
myeloid progenitors cells from Hoxa9-/- mice failed to be immortalized by MLL-ENL, the 
MLL-ENL-induced immortalization is Hoxa9 dependent [148]. Moreover, using HSCs 
from Meis1-/- embryos in MLL-fusion transformation studies revealed that Meis1 is 
essential for the transformation [149]. The Meis1 and Hoxa9 upregulation can occur 
through epigenetic alterations as seen in MLL-AF9-mediated leukemia. In this leukemia, 
Hoxa9 and Meis1 are upregulated following the H3K79 methylation mediated by 
DOT1L, an H3K79 methyltransferase [150]. 
One possible role for Meis1 in MLL-fusion-mediated transformation is through the 
regulation of the genes associated with cell cycle entry and progression such as Cdk2, 
Cdk6, Cdkn3, Ccna2, Cdc7, Cdc42, Rbl1, and Wee1. Indeed, shRNA-mediated depletion 
of Meis1 caused the reduction of the expression of these genes, reduced cell growth and 
promoted differentiation [151]. Also downregulation of MEIS1, HOXA7, HOXA9 or 
HOXA10 by shRNA impairs the engraftment of MLL-induced leukemia and decreases the 
proliferation rate of the leukemic cells in culture [152]. 
Pbx proteins are required for MLL-induced leukemogenesis and the depletion of 
Pbx2 and Pbx3 impairs leukemia formation. Moreover, the Pbx interacting domain of 
Meis1 is required for leukemic transformation mediated by MLL-fusions and Hoxa9-
immortalization [149]. 
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In addition, the maintenance of MLL-induced leukemias requires GSK-3 (glycogen 
synthase kinase 3) function. GSK-3 facilitates HOX-mediated transcription and 
transformation by inducing the conditional association of CREB transcription factor and 
its co-activators TORC and CBP to MEIS1 [153]. CREB regulates proliferation, 
differentiation, and survival in different cell types, including hematopoietic and neuronal 
cells [154]. CREB induces MEIS1 expression in normal and malignant hematopoietic 
cells by binding to the CRE sequences in the promoter region of MEIS1 which in turn 
leads to the differentiation block of primitive hematopoietic progenitor cells and the 
development of acute leukemia [155]. 
 
1.6.7.2. Role of Meis genes in Non-Hematopoietic Malignancies 
The role of Meis1 in solid tumors is poorly documented. However, the few studies 
performed to analyze the function of Meis1 in carcinogenesis suggest that Meis1 
expression in solid tumors is context-dependent. Study of MEIS and PBX gene expression 
in public human affymetrix data sets of normal (N353) and tumor (XPO1026) tissue of 
different origins revealed that in ovarian cancer, the average expression level of MEIS1 is 
3-fold higher than MEIS2 and that among the four PBX genes, PBX1 is highly expressed. 
In addition the average expression level of MEIS1 is high in ovarian and uterine cancers, 
neuroblastoma and medulloblastoma compared to the other types of tumors. The 
oncogenic function of MEIS1 and PBX1 is not well understood in ovarian carcinogenesis. 
One possible explanation for the up-regulation of these proteins in ovarian cancer is 
related to their HOX cofactor functions. Since the HOXA9-11 proteins are expressed in 
ovarian malignancies and not in normal ovary, the overexpression of their cofactors 
MEIS1 and PBX1 may enhance their oncogenic activity by increasing their DNA-binding 
affinity and specificity [130].  
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Although the MEIS genes are highly expressed in ovarian cancer, their function in 
ovarian carcinogenesis is still unclear. A recent study has shown that MEIS3, and not 
MEIS1 and MEIS2 regulates the survival of pancreatic β-cells and ovarian carcinoma cells 
through direct modulation of PDK1 (3-phosphoinositide-dependent protein kinase 1), 
which is involved in the PI3K-Akt signaling pathway. The frequent impairment of the 
PI3K-Akt signaling pathway in human cancers raises the possibility that MEIS3 functions 
in tumor cell survival through the regulation of PDK1 [156].  
MEIS1 is overexpressed in neuroblastomas [157] and is amplified in the IMR32 
neuroblastoma cell line. Analysis of the expression pattern of MEIS1 and MEIS2 in a 
broad panel of neuroblastoma cell lines and in neuroblastoma tumor samples showed 
moderate to high expression of these genes. The oncogenic role of MEIS1 in 
neuroblastoma was studied by interfering with MEIS1 function with the naturally 
occurring dominant-negative variant of MEIS1 (MEIS1E). MEIS1E lacks the C-terminal 
part of the homeodomain and therefore cannot contribute to transcriptional regulation. 
But it can compete with wild-type MEIS1 by binding to other homeobox proteins such as 
PBX. Neuroblastoma cells transfected with MEIS1E showed impaired cell proliferation, 
acquisition of differentiated phenotype, and increased contact inhibition and cell death 
which indicates a potential role for MEIS1 in neuroblastoma cell growth and proliferation 
[158]. Moreover, gene expression profiling of human sarcomas showed that MEIS1, 
MEIS2, MEIS3, and PBX1 are upregulated in leiomyosarcoma (LMS) [159]. However, 
the functional impacts of these alterations to the biology of sarcoma remain unclear. 
Although MEIS1 is implicated in the pathology of ovarian cancer, neuroblastoma, 
and sarcoma, it has been found hypermethylated or downregulated in the other subset of 
human solid tumors. But the functional relevance of these alterations and whether MEIS1 
acts as a tumor suppressor in some cellular contexts, remain fully undefined. Aberrant 
Introduction 
 
 
 50 
CpG island methylation in the promoter region of genes is a hallmark of cancer and 
occurs at early stages of tumorigenesis. Although the impact of the altered CpG 
methylation on tumor development is not well determined, it is unlikely that all of these 
methylation alterations play a causal role in tumorigenesis. CpG island hypermethylation 
silences important tumor suppressor genes and accounts for different cancers including 
breast, lung and colon cancers. These changes in DNA methylation pattern discriminate 
tumor from normal tissue. The differently methylated genes can be used as diagnostic 
biomarkers in the early stages of tumorigenesis. The CpG island of MEIS1 is methylated 
in ductal carcinoma in situ, in stage I breast tumors [160], and in squamous cell 
carcinomas of the lung [161]. MEIS1 and MEIS2 transcript downregulation were 
observed in colorectal adenomas [162] and in genome wide expression analyses of tumor 
lesions in lung adenocarcinoma induced by c-Raf-1 [163]. 
 
1.6.8. The PREP Sub-Family and Mutant Phenotypes 
 
Characterization of genes encoded by human chromosome 21 led to the discovery 
of the Pbx/KNOX1 (PKNOX1) gene [164]. At the same time, studies on the uPA 
(urokinase-type Plasminogen Activator) enhancer in human cell lines [165,166] led to the 
discovery of the same protein as a component of the regulatory complex of the human 
transcription factor UEF3. Because of its molecular properties, the newly identified 
protein was named PBX Regulating Protein1 (PREP1) [67,73]. NIH3T3 cells were used 
to isolate the murine Prep1 [167], while Prep2 was isolated by low stringency 
hybridization due to its similarity to Prep1 [117,118]. 
Mouse Prep1 null embryos have been generated by targeting the DNA-binding 
homeodomain, which abolishes protein expression. These mutant mouse embryos die 
before gastrulation at E7.5 because of massive p53-dependent apoptosis of epiblast cells 
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[168]. Moreover, in the zebrafish down-regulation of prep1.1 is embryonic lethal [169]. 
Thus the embryonic lethality of Prep1 null embryos precludes the study of the Prep1 
deficiency in the later developmental processes and in the adult animals. To overcome 
this problem, Prep1 hypomorphic mutant mice (Prep1i/i) were generated by an enhancer 
trap strategy [170]. Prep1i/i embryos express about 2% of Prep1 mRNA and 2-10% of the 
protein compared to the wild-type littermates. 75% of Prep1i/i embryos die at about E17; 
but the remaining 25% of the embryos reach term and have an almost normal life span 
[171,172]. Prep1i/i embryos apparently recapitulate in part the Meis1-/- embryos 
phenotypes by exhibiting major defects in hematopoiesis, angiogenesis and eye 
development. They also show general organ hypoplasia including liver (Figure 1.7) 
[171,172]. The hematopoietic phenotypes of the Prep1i/i embryos are due to deficiency in 
long term repopulating hematopoietic stem cells and an arrest in erythroid, B- and T-
lymphoid differentiations [171,172,173]. No loss of function mutation for Prep2 has been 
described. 
 
Figure 1.7. Gross morphology of Prep1i/i embryos compared to the wild-type 
littermate. These embryos exhibit edema, pallor, smaller size, small liver spot and 
hemorrhage. Right (R) and left (L) sides of the embryo are shown. 
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1.6.9. Prep1 Implications in Development and Cancer 
1.6.9.1. Prep1 Role in Apoptosis 
A balance between proliferation rate and programmed cell death (apoptosis) is 
crucial for normal development and organogenesis. The normal cellular balance between 
proliferation and apoptosis rates are usually disrupted in malignant growth. Among the 
TALE proteins it has been shown that the overexpression of Meis1 [132] and Pbx1 [174] 
causes massive p53-independent apoptosis. In the case of Prep1 both the depletion [175] 
and the overexpression [176] cause apoptosis, although by two different mechanisms. 
Strong spontaneous apoptosis is observed in Prep1i/i embryos at E9.5 and E11.5 
[175]. Moreover, Prep1i/i mouse embryonic fibroblasts (MEFs) from E14.5 embryos 
display an increase of basal apoptosis and accelerated response to intrinsic, but not 
extrinsic, apoptotic stimuli compared to those of wild-type littermates. The p53 transcript 
and protein level is not significantly altered in Prep1i/i MEFs. However the protein level 
of the antiapoptotic Bcl-XL protein, a regulator of mitochondrial-membrane permeability, 
is decreased [175]. Chromatin immunoprecipitation (ChIP) and transient-transfection 
analysis revealed that Prep1 directly regulates Bcl-x gene expression. The fine balance 
between pro and antiapoptotic proteins at the mitochondrial outer membrane is needed to 
regulate its permeability, thus maintaining the mitochondrial homeostasis and controlling 
apoptosis. Therefore, Prep1 influences apoptosis and modulates mitochondrial 
homeostasis by regulating Bcl-x gene expression [175]. 
Like Prep1 depleted cells, Prep1 overexpressing cells are also more sensitive to 
genotoxic stress in a p53-dependent manner. Under these conditions, p53 is a direct 
transcriptional target of Prep1 and is up-regulated in the Prep1 overexpressing cells, 
indeed, apoptosis is abrogated in these cells upon p53 down-regulation [176]. These data 
show a defined balance of Prep1 is crucial in apoptotic homeostasis [175] [176]. 
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1.6.9.2. Prep1 as a Tumor Suppressor Gene 
 The role of Prep1 in cancer is not well documented to date. However, emerging 
evidence point out that Prep1 exerts a tumor suppressive function in mouse and man. 
Almost 40% of Prep1i/i mice that survive embryonic lethality develop spontaneous 
precancerous lesions or solid tumors including lymphomas and carcinomas at different 
ages, while Prep1 wild-type mice only develop rare precancerous lesions late in life [19]. 
Furthermore, transplantation of Prep1i/i fetal liver cells induces lymphomas in lethally 
irradiated recipients. Consistent with the fact that the oncogene-driven tumorigenicity is 
accelerated in the absence of tumor suppressor genes, Prep1 haploinsufficiency (loss of 
one Prep1 allele) in the EµMyc transgenic mouse model strongly accelerates 
lymphomagenesis and death rate. Therefore Prep1 functions as a tumor suppressor in 
mice [19]. 
The deletion, mutation or silencing of tumor suppressor genes are one of the main 
features of cancer. In man, PREP1 is ubiquitously expressed in normal tissues. Its 
expression is high in breast and skin, intermediate in colon, larynx, lung bronchial 
epithelium, uterus stroma, and testicular germinal cells and low in lymph-nodes, stomach, 
kidney tubules, endometrial epithelium, uterine endo- and exocervical epithelia and 
placenta. Tissue microarray analysis revealed that PREP1 is absent or downregulated in 
most (70%) human tumors (Figure 1.7) [19]. In addition, PREP1 is located in a genomic 
region that experiences loss of heterozygosity in 31% and 50% of informative breast 
[177] and gastric cancers [178], respectively. Altogether, these pieces of evidence suggest 
that PREP1 might act as a tumor suppressor gene in human cancers. 
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Figure 1.8. Summary of PREP1 expression level in human tissue microarrays 
analyzed by immunohistochemistry. 
 
 
Genomic instability, which generates mutations and chromosomal translocations, is 
an “enabling characteristic” of cancer cells that facilitates the acquisition of cancer 
hallmarks [27]. The tumor development in Prep1i/i mice [19] and apoptosis in Prep1-/- 
epiblasts [168] and Prep1i/i MEFs [175], suggests that genetic instability might be a basic 
cellular phenotype associated with Prep1 depletion or absence. Our study on the role of 
Prep1 in maintaining genetic stability unveiled the fact that Prep1 deficient cells 
accumulate DNA damage with consequent alterations in chromatin methylation and 
satellite DNA transcription, chromosomal aberrations, escape from H-RasV12-induced 
senescence, and increased susceptibility to H-RasV12-dependent neoplastic transformation 
[179]. These data provide a cellular basis for the tumor suppressor function of Prep1 [19], 
suggesting that Prep1 depletion impairs checkpoint mechanisms involved in limiting 
oncogene-induced transformation and establishing oncogene-induced senescence in 
human cells. 
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1.7. DEAD-box RNA Helicases 
RNA and DNA helicases are encoded by a large fraction of the eukaryotic and 
prokaryotic genes. They exert enzymatic activity that unwinds the double-stranded 
nucleic acids in an energy-dependent manner. RNA and DNA helicases are divided into 
two main super-families, namely SFI and SFII, based on the occurrence of specific 
conserved motifs. The human genome encodes 64 RNA helicases and 31 DNA helicases 
[180]. RNA helicases, which are found in all organisms (from bacteria to humans), 
mostly reside in the SFII super-family.  The DEAD-box (DDX) helicases and the related 
DEAH, DExH and DExD families, commonly known as the DExD/H helicase family, are 
members of this super-family and share eight conserved motifs (Figure 1.8).  The DEAD-
box proteins were identified in the 1980s and the name of the family comes from the 
amino-acid sequence D-E-A-D (Asp– Glu– Ala– Asp) located on the Walker B motif. 
DEAD-box proteins are known as the largest RNA helicase family with 38 members in 
human. The DEAD-box family members are associated with almost all processes 
involving RNA including ribosome biogenesis, transcription, pre-mRNA splicing, RNA 
maturation, RNA export, mRNA translation and RNA decay [181,182]. Moreover, 
members of the DEAD-box family are implicated in human diseases including cancer and 
viral infections. In the next sections I will focus on two members of this family, DDX3X 
and DDX5, and their involvement in human carcinogenesis. 
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Figure 1.9. DEAD and DEAH helicases contain N-terminal and C-terminal domains 
(domain 1 and domain 2). Domain 1 and domain 2 are composed of six and three 
conserved motifs respectively. DEAD- and DEAH-boxes are located inside motif II and 
are characterized by the presence of an Asp-Glu-Ala-Asp or an Asp-Glu-Ala-His amino 
acid sequences, respectively [181].   
 
1.7.1. The Role of DDX3 in Cancer 
In man and mouse, the DDX3 gene, also named as DDX3X, CAP-Rf and DBX, maps 
to the X chromosome and is composed of 17 exons.  Human DDX3 transcript is 5.3 kb in 
size and encodes a protein of 662 amino acids. Mouse Ddx3 transcript is 4.7 kb in length 
and encodes a protein of 662 amino acids. Apart from five different amino acids, human 
and mouse DDX3 proteins are identical across the entire protein length. A functional 
homolog of this gene is located on the Y chromosome and is known as DDX3Y or DBY. 
The DDX3Y protein sequence is 91% identical with its X-linked homolog [183,184] and 
is implicated in spermatogenesis [185]. DDX3 is expressed ubiquitously [183] and 
shuttles between nucleus and cytoplasm [186]. 
The DDX3 protein was originally linked to the functions of HCV [187,188] and 
HIV [186] viruses. HCV and HIV viruses recruit DDX3 to replicate their genome 
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[186,188]. For instance, the export of HIV RNAs from the nucleus is DDX3-dependent 
[186]. Moreover, DDX3 is crucial for the HCV life cycle. Its interaction with HCV core 
protein changes the virus intracellular location [187]. In addition, several studies have 
linked DDX3 to the progression of different cancers. The role of DDX3 is controversial in 
hepatocellular carcinoma (HCC). Huang and colleagues have reported that the DDX3 
mRNA is upregulated in human HCC and is linked with the pathology of HCC [189]. 
However, another report has shown that DDX3 is downregulated in human HCC. Its 
absence in this cancer is associated with enhanced proliferation and resistance to serum-
withdrawal apoptosis induction. In fact, DDX3 depletion in NIH-3T3 cells increases 
cyclin D1 and decreases cdk inhibitor p21WAF1 levels. This leads to an enhanced transition 
from G1 to S phase and increased proliferation rate. Moreover, DDX3 knockdown in 
NIH-3T3 cells promotes v-ras-induced anchorage-independent growth [190]. 
DDX3 plays an oncogenic role in breast cancer. The exposure of breast epithelial 
cell line, MCF10A, to benzo[a]pyrene diol epoxide (BPDE) carcinogen, found in tobacco 
smoke, upregulates DDX3 expression. Also, the expression level of DDX3 is increased 
with the aggressiveness of breast cancer cell lines. The overexpression of DDX3 induces 
an epithelial-mesenchymal-like transition in non-tumorigenic MCF10A cells and 
increases their motility and invasiveness. DDX3 regulates E-cadherin expression and its 
shRNA-mediated downregulation induces E-cadherin expression [191]. DDX3 functions 
to modulate Snail transcription factor. Snail promotes epithelial-mesenchymal transition 
(EMT) by suppressing E-cadherin and several other cellular adhesion proteins. DDX3 and 
Snail levels are significantly correlated in a panel of glioblastoma multiforme tumor 
samples. Furthermore, DDX3 depletion in both MCF-7 and Hela cells decreases Snail 
levels, resulting in decreased proliferation and cellular migration. Since Snail is involved 
in EMT, its down-regulation in MCF-7 cells changes the morphology of the cells and 
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increases cellular adhesion [192]. DDX3 also exerts anti-apoptotic functions in the MDA-
MB-231 breast cancer cell line. It associates with GSK3 and cellular inhibitor of 
apoptosis 1 (cIAP-1) and prevents death receptor-induced apoptosis. Its depletion by 
shRNA promotes death receptor-induced signaling. These data suggest that DDX3 may 
contribute to resistance to death receptor-induced apoptosis in cancer cells [193]. 
DDX3 controls translation of cyclin E1 and regulates cell proliferation. DDX3 
knockdown in Hela cells suppresses cell proliferation and delays G1 to S phase transition. 
Cyclin E1 controls the G1 to S transition through Cdk2 kinase and is upregulated in many 
cancers. Since DDX3 modulates cyclin E1 translation, it may be considered as a potential 
therapeutic target in cancer therapy [194]. 
Hypoxia, as a main characteristic of solid tumors including breast cancer, changes 
gene expression programs that efficiently promote survival of cells. Low oxygen 
conditions affect the expression of hypoxia inducible factors (HIFs). HIFs act as 
transcriptional factors in the cells and mediate expression of different genes such as 
DDX3 in response to the hypoxic condition. In human breast epithelial cells HIF-1α binds 
to the consensus hypoxic response element (HRE) on the promoter of the DDX3 gene and 
increases its expression. This finding suggests that hypoxic conditions in solid tumors 
activate DDX3 expression [195]. Altogether these findings suggest that DDX3 may play 
essential regulatory roles in the development and progression of certain cancer types. 
 
1.7.2. The Role of DDX5 in Cancer 
DDX5, the prototypic member of the DEAD-box RNA helicases family, was one of 
the first examples of cellular RNA helicases, which was identified by cross-reactivity 
with PAb204 antibody raised against SV40 large T antigen three decades ago [196]. In 
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man, DDX5 (also known as p68) protein is encoded by the DDX5 gene located on 
chromosome 17 and composed of 614 amino acid residues. Ddx5 in the mouse maps to 
chromosome 11 and encodes a protein of 615 amino acids. In both man and mouse the 
DDX5 transcripts is split among 13 exons. 
Ddx5-/- embryos die at E 11.5, indicating an essential role for Ddx5 in development. 
Moreover, down-regulation of Ddx5 by RNAi reduced cell growth and enhanced 
apoptosis. Thus, Ddx5 not only is important in developmental processes but also plays a 
profound role in cell growth and survival [197]. 
DDX5 is a multifunctional protein involved in several cellular processes including 
alternative splicing [198], pre-mRNA processing [199], RNA secondary structure 
rearrangement [200], ribosomal RNA processing  [201], microRNA processing  [202] and 
transcriptional regulation [203]. DDX5 acts as transcriptional co-activator or co-repressor 
interacting with various transcription factors and nuclear receptors, including the 
myogenic regulator MyoD [204], the tumor suppressor p53 [205], androgen receptor 
[206], β-catenin [207], and the osteoblast differentiation factor Runx2 [208]. Although 
the ATPase and helicase activities of DDX5 seem to be important for its functions in 
RNA processing, they are not required for most of its transcriptional co-regulator 
activities [196]. However, p300-dependent transcription requires DDX5 ATPase activity. 
DDX5 associates with Pol II and CBP/p300 multiprotein complex and promotes 
transcription [209]. 
Different studies have shown that DDX5 expression is growth and developmentally 
regulated [210,211], suggesting a role for DDX5 in cell proliferation. DDX5 is a nucleo-
cytoplasmic shuttling protein. The intranuclear localization of DDX5 is cell cycle-related. 
DDX5 is mainly excluded from the nucleoli during interphase, but is transiently 
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associated with nascent nucleoli in late telophase [212]. This suggests that DDX5 function 
is regulated by the cell cycle.  
DDX5 is ubiquitously expressed. However, its expression and its post-translational 
modifications are altered in different cancers, suggesting that DDX5 is associated with 
cancer development [206,207,213,214,215]. DDX5 is consistently overexpressed in 
colorectal tumors and cell lines compared with the corresponding normal tissues and cells 
[213]. Furthermore, DDX5 overexpression in NIH-3T3 and NC3H10 fibroblasts results in 
the tumorigenic transformation of these cells [216], indicating a direct role for DDX5 in 
tumorigenesis.  
DDX5 is tyrosine-phosphorylated in different cancer cell lines, including colon 
tumor (Caco-2), lung carcinoma (A549), hepatocellular carcinoma (HepG2), breast 
cancer (MCF-7), cervix carcinoma (HeLa S3), and leukemia cells (K562). However, 
DDX5 is not phosphorylated in the cell lines derived from the corresponding normal 
tissues. Treatment of cancer cells with anticancer agents such as tumor necrosis factor-α 
decreases tyrosine phosphorylation(s) [214]. Treatment of the hepatic tumor cell lines, 
HT-29 and HCT116, with platelet-derived growth factor (PDGF) leads to tyrosine 
phosphorylation of DDX5 at Y593. Phosphorylated DDX5 promotes nuclear 
translocation of β-catenin by inhibiting its phosphorylation by GSK-3β. The nuclear β-
catenin then interacts with LEF/TCF complex and induces EMT [217]. 
DDX5 is overexpressed in 30 - 58% of breast tumors. Almost 70% of human breast 
tumors are ERα-positive, and since DDX5 is a co-activator of ERα, its overexpression 
may elevate the oncogenic activities of ERα [215]. The upregulation of DDX5 in breast 
tumors has been explained by strong sumoylation of the protein, which stabilizes DDX5 
and prevents its degradation [218].  
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DDX5 acts as an androgen receptor (AR) coactivator in prostate cancer. DDX5 and 
AR are recruited to the promoter region of the androgen responsive prostate-specific 
antigen gene. This finding indicates a relationship between DDX5 and AR signaling in 
prostate cancer progression [206].  
Shin et al have shown that DDX5 and its closely related homologue DDX17 (also 
known as p72) are strongly expressed during the transition from polyp to adenoma and 
from adenoma to adenocarcinoma in the colon. Moreover, they form complexes with β-
catenin and promote β-catenin-mediated transcription, for example of the proto-
oncogenes c-Myc, c-jun, cyclin D1, and fra-1. Simultaneous depletion of DDX5 and 
DDX17 reduces the expression of these β-catenin-regulated genes. Transcription of the 
cell cycle inhibitor p21WAF1/CIP1, which is suppressed by c-Myc, is increased in DDX5 and 
DDX17 knockdown cells due to the downregulation of c-Myc level. Therefore, DDX5 and 
DDX17 contribute to colon cancer development through direct upregulation of proto-
oncogenes and through indirect down-regulation of the growth suppressor p21WAF1/CIP1. 
Accordingly, DDX5 and DDX17 depletion in colon cancer cells prevents their 
proliferation and decreases their tumor formation ability in vivo [207]. 
 
1.8. Aim of The Thesis 
The highly related members of TALE class homeodomain transcription factors, 
MEIS1 and PREP1, employ their homology domain (HR) to interact with PBX family 
members. They are also able to interact with HOX family members and bind similar 
DNA sequences in some cases. However, they have evolved to exert opposite effects in 
tumorigenesis. The oncogenic member of the family, MEIS1, accelerates HOX- and MLL-
induced leukemias and promotes tumor progression in some solid cancers. PREP1, 
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however, appears to have a tumor suppressive function. Accordingly, Prep1i/i mice, which 
escape embryonic lethality, develop tumors or precancerous lesion later in life. Thus, the 
lack of information on the role of MEIS1 in non hematological malignancies and its 
possible competition with PREP1 in this context prompted me to unravel molecular 
mechanisms underlying Meis1 oncogenicity and its possible competition with Prep1 
using MEFs as a model system. 
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2.1. Prep1i/i MEFs are more prone to immortalization by the 3T3 
protocol. 
I used a 3T3 protocol to analyze the immortalization rate of two Prep1wt and two 
Prep1i/i littermate MEF cultures. 3T3 protocol is defined as the passage of 3 × 105 cells 
every 3 days in 50 mm dishes. Passaging primary cells with a 3T3 protocol maximizes the 
growth before they develop cellular senescence [219]. The population doubling level 
(PDL) was identical in the two genotypes up to passage 9 (Figure 2.1). From passage 9 to 
34, Prep1wt MEFs grew with lower PDL than Prep1i/i MEFs. After passage 20, Prep1i/i 
MEFs markedly increased their proliferative capacity [179].   
 
 
 
Figure 2.1. Early immortalization in Prep1i/i MEFs. 3 × 105 cells from two individually 
derived primary MEFs of each genotype were plated in 6 cm dishes. Cells were 
trypsinized and counted every three days based on the 3T3 protocol. Cells were kept in a 
3% O2 incubator during the entire experiment time. Averaged growth curves from two 
individually derived primary MEFs of each genotype. Error bars indicate SEM; *P < 
0.05. 
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2.2. The growth rate of early passage Prep1i/i and Prep1wt MEFs is 
identical but late passage Prep1i/i MEFs proliferate faster than their 
Prep1wt counterpart. 
To check the effect of Prep1 absence on the proliferation rate of MEFs, I analyzed 
the growth rate of one primary Prep1i/i and two Prep1wt littermates MEF cultures at 
passage 2 (Figure 2.2A, upper panel) or two immortalized Prep1i/i and Prep1wt MEFs at 
passage 33 (Figure 2.2B, upper panel). Cells were immortalized using 3T3 protocol (See 
section 2.1). The proliferation rate of primary Prep1i/i and Prep1wt cells does not show any 
difference in early passage cells; however, immortalized Prep1i/i cells proliferate faster 
than WT cells. The protein level of Prep1 in primary (Figure 2.2A, lower panel) and 
immortalized (Figure 2.2B, lower panel) Prep1i/i and Prep1wt MEFs was tested by 
immunoblotting.  
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Figure 2.2. Cell proliferation rate of primary and immortalized Prep1i/i and Prep1wt 
MEFs. To compare the growth rate between primary Prep1i/i and Prep1wt MEFs (A) and 
between immortalized Prep1i/i and Prep1wt MEFs (B), 1 × 105 passage-two cells and 5 × 
104 passage-33 cells were plated in 6-well plates in triplicate. Cells were trypsinized and 
counted every day or every other day. Data represent the average of three independent 
wells. Error bars indicate SD. *P > 0.05. Total lysates of primary and immortalized 
Prep1i/i and Prep1wt MEFs were analyzed by western blotting using Prep1 polyclonal 
antibody. Vinculin was used as the loading control. 
 
2.3. Prep1-deficiency does not alter Meis1 mRNA and protein level in 
primary MEFs, but decreases its protein level in immortalized cells. 
Deficiency of Prep1 affects the stability of Pbx1 and Pbx2 proteins in mouse 
embryos and therefore decreases their level [171,173]. In this regard, I checked whether 
the lack of Prep1 had any effect on the mRNA and protein level of the oncogenic member 
of the TALE family proteins, Meis1. To address this point, qPCR was performed on the 
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cDNA prepared from 3 different Prep1i/i and 3 different Prep1wt primary MEFs cultures. I 
observed no major differences in the levels of expression of the Meis1 mRNA in Prep1i/i 
compared to Prep1wt MEFs (Figure 2.3A). The levels of Meis1a protein also are not 
particularly changed in these cells (Figure 2.3B). However, in immortalized MEFs, Meis1 
protein level is significantly decreased in Prep1-deficient cells compared to the WT 
counterparts (Figure 2.3C). Although its mRNA level is not altered in these cells (data are 
not shown). Therefore the deficiency of Prep1 has no significant effect on the expression 
of Meis1 in primary cells but it decreases Meis1 protein level in immortalized cells. 
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Figure 2.3.  Effect of Prep1 deficiency on Meis1 expression level (A) Total RNA was 
extracted from passage-3 MEFs. RNA was retrotranscribed and qPCR analysis performed 
using specific primers for Prep1 and Meis1 genes. GAPDH was used for normalization. 
The results are plotted as the mean of 3 different Prep1i/i and 3 different Prep1wt MEFs 
cultures. (P > 0.05) (B) Nuclear extracts of the same cells were analyzed by western 
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blotting using Meis1 K845 antibody. Nucleolin was used as the loading control. 
Quantification of the bands was done by densitometric analysis and plotted as the mean of 
three different Prep1i/i and three different Prep1wt MEFs cultures (P > 0.05). Error bars 
indicate SD. (C) Nuclear extract of two Prep1wt and two Prep1i/i immortalized cells was 
prepared and analyzed by western blotting using Meis1 K845 antibody. PCNA was used 
as the loading control. Bands were quantified by densitometric analysis and plotted as the 
mean of two different Prep1i/i and two different Prep1wt immortalized MEFs (P < 0.05). 
Error bars indicate SD. 
 
 
2.4. Meis1a induces proliferation in p53ko primary and Prep1i/i 
immortalized but not in Prep1i/i primary MEFs. Meis1a cooperates with 
Ras or c-Myc in p53wt primary MEFs. 
 Transformation of primary rodent fibroblasts needs the coexpression of at least two 
oncogenes or overexpression of one oncogene in the absence of a tumor suppressor gene, 
whereas a single oncogene is generally sufficient in immortalized cells [219,220]. To 
check the oncogenecity of Meis1 in primary MEFs, p53ko and WT MEFs at passage-3 
were infected with a retroviral vector encoding oncogenic H-Rasv12, Meis1a or an empty 
vector as control. Moreover WT cells were infected with a combination of H-Rasv12/c-
Myc, H-Rasv12/Meis1a and c-Myc/Meis1a retroviruses. H-Rasv12, c-Myc and Meis1a 
expression were confirmed by immunoblotting (Figure 2.4A and 2.4C). I subjected these 
cells to growth curve assay (Figure 2.4B and 2.4D). Like Ras, Meis1a, did not accelerate 
the proliferation of p53wt primary MEFs, but it did so in p53ko cells. The coexpression of 
Meis1a with H-Rasv12 or with c-Myc, however, increased proliferation in the WT cells 
(Figure 2.4B and 2.4D). Moreover, when Prep1i/i MEFs at passage-3 were infected with a 
retrovirus vector encoding Meis1a, I did not observe any proliferation difference between 
Meis1a-overexpressing and control cells (data not shown). I, therefore, used immortalized 
MEFs to test whether Meis1a alters the proliferation of cells in the absence of Prep1. I 
transduced passage-30 MEFs with a retrovirus encoding Meis1a. Infected cells were 
selected with puromycin, and Meis1a expression level was confirmed by immunoblotting 
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(Figure 2.4E). Meis1a over-expressing Prep1i/i cells proliferated faster than WT (Figure 
2.4F). Altogether, this data shows that Meis1a alone can accelerate the proliferation of 
primary MEFs in the absence of p53. However, in the WT cells it requires a cooperating 
oncogene. Moreover, in the absence of Prep1, Meis1a accelerates the proliferation of 
immortalized MEFs. This agrees with the tumor suppressor function of Prep1. 
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Figure 2.4. Meis1a-induced proliferation in MEFs. Passage-3 p53wt (B)  and p53ko (D)  
cells were infected with Ras, Meis1a, c-Myc or a retroviral combination of Ras/c-Myc, 
Ras/Meis1a, c-Myc/Meis1a or empty vector as shown. The expression level of the 
indicated genes was checked by immunoblotting (A and C) . 2.5 × 104 infected cells 
were plated in 12-well plates in triplicate and cells counted at the indicated time points (B 
and D). Passage-33 Prep1i/i and WT MEFs were infected with Meis1a and subjected to 
growth curve assay over a 7-days period. 5 × 104 infected cells were plated in 6-well 
plates in triplicate and counted at the indicated time points (F). Exogenous Meis1a 
expression level was checked by western blotting using anti FLAG antibody. Nucleolin 
was used as a protein loading control (E). Data represent the means of three independent 
wells. Error bars indicate SD. *P < 0.001; **P < 0.01. 
 
2.5. Meis1a overexpression malignantly transforms Prep1i/i but 
not Prep1wt immortalized MEFs. The effect is partially reverted 
by Prep1 re-expression.  
Loss of contact inhibition in monolayer culture and anchorage-independent growth 
are the characteristics of oncogene-induced cell transformation. They are useful assays in 
vitro to test the tumorigenicity of cells [221,222]. I did not observe formation either of 
colonies in soft agar or tumors in mice when Prep1i/i or WT passage-3 MEFs were 
infected with a retrovirus vector encoding Meis1a (data not shown). I, therefore, used 
immortalized MEFs to test whether Meis1a alone transforms Prep1-deficient cells. Since 
Meis1 and Hoxa9 cooperate to transform hematopoietic cells [43], I retrovirally infected 
passage-35 MEFs with Meis1a, Hoxa9 or with a combination of the two retroviruses. The 
infected cells were first analyzed for foci formation when seeded in low number. Prep1-
deficent cells formed almost twice more colonies compared to the WT cells when 
infected with Meis1a/Hoxa9 or Meis1a only retroviruses. However, Prep1i/i and not WT, 
cells formed few foci when infected with the sole Hoxa9 retrovirus (Figure 2.5A). 
When infected cells were analyzed for anchorage independent growth in semi-solid 
medium, Meis1a-Hoxa9 coexpressing Prep1i/i cells formed colonies in agar 3-fold more 
efficiently than WT. Also the colonies of Prep1i/i cells were bigger than those of WT cells 
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(Figure 2.5B and 2.5C). Surprisingly, overexpression of Meis1a alone in Prep1i/i cells 
induced colony formation in agar. This property was significantly inhibited by Prep1 re-
expression (Figure 2.5B and 2.5C).  
Consistent with these data, subcutaneous transplantation of the infected cells into 
immunodeficient mice revealed a significant difference between the tumorigenicity of 
WT and Prep1i/i cells overexpressing Meis1a. Only Prep1i/i, and not WT, cells 
overexpressing Meis1a formed tumors in mice (Figure 2.5D and 2.5E). In addition, 
Prep1i/i cells coexpressing Meis1a-Hoxa9 formed more aggressive tumors than WT cells 
as measured by the volume of the tumor but neither Prep1i/i nor WT cells overexpressing 
Hoxa9 alone were able to form tumor (Figure 2.5D and 2.5E). I tested whether Prep1 re-
expression can affect the tumorigenic activity of Meis1. To this goal, I first overexpressed 
Meis1a in Prep1i/i cells, then divided the cells in two groups re-infecting them with either 
empty vector or Prep1 vector. Remarkably Prep1 re-expression decreased tumor growth 
of the Prep1i/i cells overexpressing Meis1a and increased the latency of Meis1a-induced 
tumor (2.5D and 2.5E). Cells transduced with H-Rasv12 and c-Myc retroviruses were used 
as positive control for tumor formation. The inability of Hoxa9 to induce tumors in 
Prep1i/i cells is surprising and will deserve further investigation. The overexpression level 
of the indicated genes is shown in figure 2.5 F. 
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Figure 2.5. Effect of Meis1a on transformation and tumorigenicity of Prep1i/i and 
WT MEFs. Retrotransduced MEFs colony formation assay (A) and anchorage-
independent soft agar growth assay (B and C). (A) The upper panel shows the examples 
of the plates seeded with 5 × 103 cells. The percentage of the colonogenic cells from two 
independent experiments, each performed in triplicate, is shown in the lower panel. Error 
bars represent SD. The number (B) and the size (C) of colonies formed in soft-agar by 
105 Prep1i/i and WT MEFs per 6cm plate, infected with the indicated retroviruses are 
shown (*P< 0.001 compared with Prep1i/i MEFs re-expressing Prep1; **P< 0.001 
compared with wt MEFs overexpressing Prep1). Data represent the mean of three 
independent plates. Error bars indicate SD. WT (D) and Prep1i/i MEFs (E) retrovirally 
transduced with the indicated vectors were subcutaneously injected into nude mice (1 × 
106 cells per animal) and tumor volume was monitored. Lines represent the average of 
five animals per group. For clarity the SD is not shown. Differences between Prep1i/i 
overexpressing Meis1a and Meis1a together with Prep1 groups (*P< 0.05) were 
statistically significant. (F) Immunoblots show the overexpression levels of Prep1, 
Meis1a and Hoxa9 in cells infected with the indicated retroviruses. PCNA was used as a 
protein loading control.  
 
 
2.6. The HR1+2 domain of Prep1 is required to inhibit Meis1-induced 
transformation.  
Identification of the domains of Prep1 responsible for the inhibition of 
tumorigenesis can give information on the mechanism. To identify the domains of Prep1 
required to inhibit Meis1 tumorigenicity, I constructed different Prep1 mutants and tested 
their effect on Meis1-induced cell transformation both in vitro and in vivo. To do so, 
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several deletion mutants introducing the following modifications were subcloned in 
pMSCV-hygro vector along with a FLAG-tag: a) deletion of the Pbx interacting domain 
(Prep1ΔHR1+2, deleted residues: 58-137); b) deletion of the DNA binding homeodomain 
(Prep1ΔHD, deleted residues: 259-318); c) deletion of the C-terminal domain (Prep1ΔC, 
deleted residues: 318-436) (Figure 2.6A). 
The expression of each Prep1 mutant was checked by semiquantitative RT-PCR and 
western blotting in infected passage-35 Prep1i/i MEFs. The semiquantitative RT-PCR 
analysis showed that all mutants were well expressed at the mRNA level (Figure 2.6B). 
The WT and mutated cDNAs produced proteins of the predicted molecular weight as 
determined by western blotting (Figure 2.6C upper panel). Moreover the subcellular 
localization of the different mutant proteins was also tested using nuclear and cytoplasmic 
lysates. Except Prep1ΔHR1+2, which shows both nuclear and cytoplasmic localizations, 
the other mutants were mainly nuclear (Figure 2.6C upper panel). 
 To test the effect of different Prep1 mutants on Meis1-induced tumorigenesis, I 
infected passage-35 Prep1i/i MEFs with FLAG-tagged Meis1a retroviruses. After 
selection of the infected cells with puromycin, cells were retrovirally infected with 
different FLAG-tagged Prep1 mutants and selected with hygromycin B. The expression 
of exogenous Meis1a and Prep1 mutants was checked by western blotting with an anti-
FLAG antibody. Moreover, the Meis1a level was also checked by specific anti-Meis1 
antibody (Figure 2.6C middle panel). Unexpectedly, the overexpression of both Prep1 
and Prep1 mutants except Prep1ΔHR1+2 decreased Meis1a protein level of almost to 4- 
to 5-fold depending on the antibody (anti-FLAG versus anti-Meis1) (Figure 2.6C lower 
panel).  
Infected cells were subjected to anchorage independent growth in semi-solid 
medium and the colonies were scored after 2 weeks. Overexpressed Prep1, Prep1ΔHD 
and Prep1ΔC proteins significantly reduced Meis1a induced colonies. The full length 
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Prep1 decreased the number of colonies by almost 3-fold, and the mutants by 2-fold. 
Prep1ΔHR1+2 did not show any inhibitory effect on the Meis1-induced transformation 
(Figure 2.6D). When cells transduced with Meis1a and different Prep1 mutants were 
injected in immunodeficient mice, Prep1ΔHD and ΔC mutants still inhibited Meis1-
induced tumors, whereas Prep1ΔHR1+2 mutant failed to decrease tumor growth (Figure 
2.6E). This result indicates that the HR1+2 domain of Prep1 contributes significantly to 
its tumor suppressive function.  
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Figure 2.6. Identification of the Prep1 domain involved in inhibiting Meis1-induced 
transformation. (A) Schematic representation of Prep1 and Prep1 mutants, showing the 
position of the Pbx interacting domain (HR1+2), homeodomain (HD) and C-terminus. 
Blank spaces represent deletions. (B) Total RNA was extracted from passage-35 Prep1i/i 
MEFs stably expressing different Prep1 mutants. RNA was retrotranscribed and a 
semiquantitative PCR was performed using specific primers for Prep1 mutants and 
GAPDH cDNA. (C, upper panel) 30 µg of nuclear and 60 µg of cytoplasmic lysates 
0 
100 
200 
300 
400 
500 
600 
700 
800 
900 
11 15 18 20 22 
Tu
m
or
 V
ol
um
e 
(m
m
3)
 
Days after inoculation 
Meis1a 
Meis1a+Prep1 
Meis1a+Prep1!HR1+2 
Meis1a+Prep1!HD 
Meis1a+Prep1!C 
Empty vector 
E 
* 
* 
D 
0 
100 
200 
300 
400 
500 
600 
Me
is1
a 
Me
is1
a+
Pre
p1
 
Me
is1
a+
Pre
p1
!H
R1
+2
 
Me
is1
a+
Pre
p1
!H
D 
Me
is1
a+
Pre
p1
 !C
 
em
pty
 ve
cto
r 
C
ol
on
y 
N
um
be
r 
* ** 
Results 
 
 
 81 
were analyzed by immunoblotting with Prep1 antibody. PCNA and Vinculin were used as 
loading control for nuclear and cytoplasmic lysates, respectively. The position of FALG-
Prep1 and each mutants is shown by an asterisk. (C, middle panel) 30 µg of nuclear 
lysate was analyzed by immunoblotting with Prep1, FLAG and Meis1 antibodies. PCNA 
was used as loading control. The position of FLAG-Meis1a is shown by an arrow and the 
position of FLAG-Prep1 and each mutants is shown by an asterisk. (C, lower panel) 
Densitometric analysis performed using ImageJ (normalized to the level of PCNA).  (D) 1 
× 105 Prep1i/i MEFs retrotransduced with Meis1 and Prep1 mutants were subjected to 
anchorage-independent soft agar growth assay. The number of colonies formed after 2 
weeks of culturing is shown (*P < 0.01 compared with Prep1i/i MEFs re-expressing 
Prep1; **P < 0.0001 compared with Prep1ΔHR1+2 overexpressing cells). Data represent 
the mean of three independent wells. Error bars indicate SD. (E) Prep1i/i MEFs 
overexpressing Meis1a along with Prep1 or Prep1 mutants were subcutaneously 
transplanted into nude mice (1 × 106 cells per animal) and the tumor volume was 
monitored. Lines represent the average of five animals per group. For the sake of clarity 
SD is not shown.  Differences between Prep1i/i overexpressing Meis1a and Meis1a plus 
Prep1, Prep1ΔHD or Prep1ΔC groups are statistically significant (*P< 0.05). 
 
2.7. Subcellular localization of WT and mutants Prep1. 
Since Prep1ΔHR1+2 mutant is not capable of inhibiting Meis1-induced 
transformation, I wanted to see whether this impairment was due to the inability of this 
mutant to translocate to the nucleus, since its nuclear translocation depends on the 
interaction with Pbx [75]. In this regard, I analyzed the subcellular localization of 
different Prep1 mutants expressed in MEFs. I retrovirally infected passage-35 Prep1i/i 
MEFs with the different Prep1 mutants (Figure 2.6A) and checked the expression of each 
mutant by western blotting on the nuclear extract. (Figure 2.6C). To check the subcellular 
localization of different mutants by immunoflorescence and confocal microscopy, 
infected cells were plated on poly-D-lysine treated coverslips. The day after, coverslips 
were fixed in 4% PFA and stained with Prep1 polyclonal antibody and DAPI. This 
already known that the deletion of the Pbx interacting domain of Prep1 (HR1+2) impairs 
its nuclear localization [75]. However, here I observed that Prep1ΔHR1+2, in addition to 
a clear cytoplasmic localization, could still be detected in the nuclear compartment, 
possibly indicating that other mechanisms may exist in its nuclear translocation. The 
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RGB profile of the HR1+2 construct shows only a partial area of co-localization of Prep1 
and DAPI. The other mutants did not show any nuclear localization impairment when 
analyzed by confocal microscopy, as expected (Figure 2.7). 
 
 
 
 
 
 
 
Figure 2.7. Subcellular localization of different Prep1 mutants. (panel A) Cells 
overexpressing different Prep1 mutants were analyzed by immunofluorescence and 
confocal microscopy after fixation and staining with DAPI (blue) and Prep1-Cy5 
antibody (Red). Cells infected with empty vector were used as control. The nuclear dye 
DAPI was used to counterstain nuclei. Panel B represents the zoom of the selected areas 
in the images shown in panel A. The RGB profiles on the right show the extent of co-
localization of DAPI (blue line) and Prep1 (red line) staining. 
 
2.8. Prep1ΔHR1+2 mutant does not interact with Pbx1 and Pbx2 and 
does not alter their levels in Prep1i/i cells. 
In mammalian cells, overexpression of Prep1 increases the stability of Pbx1 and 
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Pbx2 by preventing their proteasomal degradation [76]. Moreover in mouse embryo, 
Prep1 deficiency decreases the protein level of Pbx1 and Pbx2 [171], both of which can 
interact with Prep1. To explain the inability of Prep1ΔHR1+2 to inhibit Meis1-induced 
tumor formation, I checked the effect of each Prep1 mutant overexpression on the Pbx1 
and Pbx2 protein levels and their ability to interact with Pbx proteins. Pbx1 and Pbx2 
protein levels were assessed by western blotting in Prep1i/i MEFs infected with FLAG-
tagged versions of Prep1, Prep1ΔHR1+2, Prep1ΔHD or Prep1ΔC retroviruses (figure 
2.8A). As shown in the graph, the Prep1ΔHR1+2 mutant is the only mutant unable to 
increase Pbx1 and Pbx2 protein levels. The interaction of each mutant with Pbx1 and 
Pbx2 proteins was checked by immunoprecipitation (IP) with anti-FLAG antibody 
followed by immunoblotting with specific antibodies. Also in this case, Prep1ΔHR1+2 
was the only mutant unable to interact with these proteins, as expected [75]. The defect of 
this mutant in interacting with Pbx proteins may explain its inability to inhibit Meis1-
induced tumorigenicity. The other mutants showed no defect both in the increase of, and 
in the interaction with Pbx1 and Pbx2 proteins. 
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Figure 2.8. The HR1+2 domain is required for interaction with Pbx proteins and 
their subsequent stabilization. (A) Immunoblot performed on the nuclear lysates 
prepared from infected cells and tested for Pbx1 and Pbx2 using appropriate antibodies. 
PCNA was used as loading control. The densitometric analysis was performed using 
ImageJ (normalized to the level of PCNA). (B) 300 µg of the nuclear extracts of the 
Prep1i/i MEFs infected with FLAG-tagged Prep1 and Prep1 deletion mutants or with 
empty vector were immunoprecipitated with M2 anti-FLAG antibody and immunoblotted 
with the anti Prep1, Pbx1 and Pbx2 specific antibodies. 1/10 of the lysate used for 
immunoprecipitation was loaded as inputs.  
 
2.9. Purification and identification of Meis1a interacting proteins by 
TAP and mass spectrometry respectively. 
 In order to gain further insights into the molecular mechanisms underlying Meis1a 
oncogenic activity and its interruption by Prep1 re-expression, I purified Meis1a 
interactors in the Meis1a overexpressing WT, Prep1 deficient and Prep1 deficient cells 
re-expressing Prep1, using Tandem Affinity Purification (TAP) (Figure 2.9A). For this, I 
generated a TAP-tagged Meis1a retroviral construct and retrovirally infected 
immortalized Prep1i/i and Prep1wt MEFs. Prep1i/i cells overexpressing Meis1a-TAP were 
also secondarily infected with Prep1-coding retroviruses. Before performing TAP, I 
checked the functionality of Meis1a-TAP protein by subcutaneous transplantation of the 
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cells overexpressing Meis1a-TAP. As expected, only Prep1i/i cells overexpressing 
Meis1a-TAP and not WT cells formed tumor in the transplanted nude mice (Data not 
shown). TAP was performed on the nuclear extracts of Prep1i/i and Prep1wt MEFs and 
also on the nuclear extracts of Prep1i/i cells re-expressing Prep1.  Purified proteins were 
run on SDS-PAGE (Figure 2.9B) and were identified by mass spectrometry analysis This 
analysis revealed that Meis1a is associated with the other member of TALE family 
proteins Pbx1, as previously reported in MLL-induced leukemia [149] (Table 2.1). It also 
interacts with the other member of this family, Pbx2. Moreover, Meis1a is associated with 
p160 myb-binding protein, which has been also shown to interact with Prep1 through the 
HR1 domain [72,223]. However, no peptides of Prep1 were found in the MS analysis, 
indicating that Meis1a and Prep1 do not form a complex. In addition, we identified a 
series of novel non-homeodomain proteins that co-purified with Meis1a only in Prep1i/i 
and not in WT cells nor in Prep1i/i cells re-expressing Prep1 (Table 2.1). Of these 
proteins, two ATP-dependent RNA helicases known as Ddx5 and Ddx3x co-purified with 
Meis1a only in the absence of Prep1. The complete list of the Meis1a interacting proteins 
along with the information about mascot score and emPAI index of each interactor are 
shown in Table 2.1. Some of these interactions were further validated by immunoblotting 
of the TAP purification product with appropriate antibodies (Figure 2.9C). The 
recruitment of the Ddx5 and Ddx3x RNA helicases by Meis1 only in Prep1i/i and not in 
WT cells or Prep1i/i cells overexpressing Prep1 suggests that these proteins play a role in 
the Prep1 inhibition of Meis1 tumorigenicity. For example, they might play a role in 
promoting active transcription from promoters bound by Meis1a in the absence of Prep1. 
Therefore I assessed the biological relevance of Meis1 interaction with Pbx1, Ddx3x and 
Ddx5 proteins in the context of tumor formation. 
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Figure 2.9. Protein composition of TAP-purified Meis1a. (A) Schematic representation 
of the tandem affinity purification (TAP) protocol. TAP tag is composed of three different 
components: Protein A as an immunoglobulin G (IgG)-binding domain, a tobacco etch 
virus (TEV) protease cleavage site and a calmodulin-binding domain. TAP-tagged Meis1 
was expressed in Prep1wt, Prep1i/i and Prep1i/i MEFs re-expressing Prep1 and purified 
using rabbit (IgG) agarose beads. Then the purified complexes were eluted by TEV 
protease cleavage (first affinity column). The remaining complex after TEV cleavage was 
purified using calmodulin beads (second affinity column) and eluted by boiling in SDS 
sample buffer. (B) The final TAP eluate was separated on a 10% SDS-PAGE and stained 
by colloidal coomassie blue. The entire lane was cut out from the gel and divided into 
different zones. Protein complex compositions of each zone were identified by LC-
MSMS and are listed in table 2.1. Exponentially modified protein abundance index 
(emPAI) is indicated as measure of relative quantitation of proteins in each sample. A 
purification from cells infected with TAP empty vector is presented as negative control 
(TAP). (C) Immunoblots of TAP purified proteins from the TAP eluate of nuclear 
extracts of the indicated cells, using specific antibodies. 
 
2.10. Ddx3x and Ddx5 proteins co-precipitate only with Meis1a and not 
Prep1. Prep1 protein level restoration in Prep1i/i cells impairs the 
interaction. 
Among the novel Meis1a interactors, I focused on Ddx3x and Ddx5 RNA helicases, 
because they copurified with Meis1a only in the absence of Prep1 protein. Indeed Meis1a 
induces transformation of Prep1-deficient but not WT MEFs, and Prep1 re-expression 
partially inhibits tumor formation. Thus these RNA helicases might be novel Meis1a 
interactors, which associate with Meis1a and promote cellular transformation only in the 
absence of Prep1. Indeed, these genes have been shown to be involved in the cancer (see 
introduction) [191,207]. To confirm Meis1a interaction with Ddx3x and Ddx5, I 
retrovirally infected Prep1i/i and Prep1i/i MEFs re-expressing Prep1 with FLAG-tagged 
Meis1a and empty vector as negative control. FLAG-tagged Meis1a overexpression did 
not alter the nuclear level of Ddx3x and Ddx5 proteins (figure 2.10A Input panel). FLAG-
tagged Meis1a was immunoprecipitated with an M2 anti-FLAG affinity resin from 
nuclear lysates of the infected cells and immunoblotted using specific Ddx3x, Ddx5, 
Pbx1, Pbx2 and anti FLAG anibodies (Figure 2.10A IP panel). Overall, these experiments 
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revealed that Meis1a, Ddx3x and Ddx5 can form a stable complex in vivo in the absence 
of Prep1. However, Pbx1 and Pbx2 form complexes with Meis1a both in the absence and 
in the presence of Prep1. 
Furthermore, I performed co-immunoprecipitation to investigate whether Meis1a 
interaction with Ddx3x and Ddx5 RNA helicases is specific to the oncogenic member of 
the TALE family or it also extends to the tumor suppressive member of the family, Prep1 
[19]. I retrovirally infected Prep1i/i MEFs with FLAG-tagged Prep1, Prep1 deletion 
mutants and empty vector as negative control. Prep1 deletion mutants have been 
described in section 2.6. The overexpression of different Prep1 mutants did not affect the 
nuclear level of Ddx3x and Ddx5 proteins (Figure 2.10B Input panel). Nuclear lysates of 
the cells infected with Prep1 deletion mutants’ retroviruses were immunoprecipitated with 
an M2 anti-FLAG affinity resin and immunoblotted using specific Ddx3x, Ddx5, Meis1 
and Prep1 antibodies (Figure 2.10B). The results show that neither full-length Prep1 nor 
any of the Prep1 deletion mutants forms a complex with these proteins. Although Pbx1 
and Pbx2 co-immunoprecipitation with Prep1 showed that the co-IP worked (see figure 
2.8B). Therefore the Ddx3x and Ddx5 interaction is specific to the oncogenic Meis1. 
Moreover, Meis1 also does not immunoprecipitate with Prep1, as expected. 
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Figure 2.10. Ddx3x and Ddx5 interact specifically with Meis1 and not Prep1. (A) 300 
µg of the nuclear extracts of the Prep1i/i MEFs infected either with FLAG-tagged Meis1a 
alone, along with Prep1 or empty vector was immunoprecipitated with M2 anti-FLAG 
antibody and immunoblotted with the anti FLAG, Ddx3x, Ddx5, Pbx1 and Pbx2 specific 
antibodies. 1/10 of the lysate used for immunoprecipitation was loaded as input. (B) 
FLAG-tagged Prep1 and FLAG-tagged Prep1 mutants were immunoprecipitated from 
300 µg of nuclear extracts of the cells infected with these mutants using M2 anti-FLAG 
antibody. Lysate from cells infected with empty vector was used as negative control. The 
Prep1, Prep1 mutants, Pbx1 and Pbx2 in the input and precipitated samples were 
identified by western blotting using appropriate antibodies. 
 
2.11. Ddx3x interacts with the homeodomain and Ddx5 interacts with 
both the homeodomain and the C-terminus of Meis1a. 
To map the Meis1a domains required for the interaction with Ddx3x and Ddx5, I 
generated the following GST-Meis1a deletion mutants (Figure 2.11A): a) Deletion of the 
DNA binding homeodomain and C-terminus of Meis1a (Meis1aΔHD+Cter, deleted 
residues: 267-390); b) Deletion of the N-terminus and Pbx interacting domain of Meis1a 
DNA (Meis1aHD+Cter, deleted residues: 1-266); c) Deletion of both N- and C-terminal 
sequences, generating Meis1a DNA binding homeodomain (Meis1aHD, residues: 267-
338); d) Deletion of the whole N-terminus plus homeodomain, generating Meis1a C-
terminal domain (Meis1aCter, residues: 339-390). I performed a pull-down assay with the 
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nuclear lysate of the Prep1i/i MEFs overexpressing Meis1a. GST was used as a negative 
control to check the specificity of the interactions. Figure 2.11B (Bottom panel) shows 
the Coomassie staining of the GST and GST-Meis1a mutants’ preparations. Figure 2.11B 
(upper panel) shows the specific interaction of both Ddx3x and Ddx5 with the Meis1aHD 
and in the case of Ddx5 also with the C-terminal part of Meis1a. No interaction was 
observed with a construct containing the N-terminus and the Pbx interacting domain only. 
Even if Ddx3x interacts specifically with the HD of Meis1a, there is 50% reduction of 
Ddx3x binding efficiency to the HD compared to the full-length Meis1a (Figure 2.11C 
upper graph). Apparently, Ddx3x does not interact with the C-terminus of Meis1a, while 
Ddx5 interacts with HD+Cter almost as efficiently as with the full-length Meis1a. Ddx5 
interaction with either HD or C-terminus of Meis1a is 2.5-fold less efficient than with the 
HD+Cter construct (Figure 2.11C lower graph). This suggests that Ddx5 interaction 
requires both the HD and the C-terminus of Meis1a. Neither Ddx3x nor Ddx5 interact 
with the N-terminus and Pbx-interacting domains (HR1+2) of Meis1a (Figure 2.11C).  
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Figure 2.11. Identification of the Meis1a domains required for Ddx3x and Ddx5 
interactions. (A) Schematic representation of GST-Meis1a deletion mutants. Pbx 
interacting domains (HR1 and HR2) and DNA binding domain (HD) are indicated. (B) 
After coupling of GST-constructs to the beads, GST and GST-Meis1a deletion mutant 
beads were blocked with BSA to prevent non-specific bindings. GST beads were 
incubated with 300 µg of the nuclear lysates from Meis1a overexpressing Prep1i/i cells. 
Western blot with Ddx3x and Ddx5 specific antibodies was performed to reveal 
interaction with Meis1a domains (upper panel). The position of each GST-construct is 
shown by an asterisk (bottom panel). (C) Immunoblots were normalized on the bands of 
the each GST-constructs obtained from Coomassie stained gel using ImageJ and were 
plotted as binding efficiency of either Ddx3x or Ddx5 compared to each GST-constructs. 
 
2.12. Meis1-mediated transformation and Prep1-inhibition of Meis1 
tumorigenesis require the homeodomain protein Pbx1.  
Analysis of the Meis1 interactome by mass spectrometry confirmed the interaction 
between Meis1 and TALE homeodomain proteins Pbx1 and Pbx2 (Section 2.9). On the 
other hand also Prep1 interacts with Pbx1 and Pbx2, using the same interaction surface 
(HR1+HR2) [75]. Prep1, however partially inhibits Meis1 tumorigenicity. To assess the 
biological relevance of Pbx1 in Meis1-induced tumorigenicity and its inhibition by Prep1, 
Prep1i/i MEFs overexpressing Meis1a or Meis1a and Prep1 were depleted of Pbx1 by 
specific shRNAs. This resulted in 80 - 90% reduction of Pbx1 protein level (Figure 2.12A 
upper panel). Pbx1 depletion did not have any major effect on the level and subcellular 
localization of overexpressed Meis1a and Prep1 (Figure 2.12A lower panel). Importantly, 
Prep1 overexpression reduced the Meis1a protein level by 2.6-fold (also see figure 2.6C). 
However, Pbx1 knockdown resulted in almost 2-fold and 3-fold increase of Pbx2 in 
Meis1a and Meis1a/Prep1 overexpressing cells, respectively (Figure 2.12A lower panel). 
The consequences of Pbx1 depletion on the proliferation and tumorigenic potential of 
these cells were studied. The effect of Pbx1 downregulation on the cell proliferation was 
assessed by growth curve assay and cell cycle analysis by FACS. Pbx1-depleted Meis1a 
overexpressing cells proliferated almost as efficiently as the scrambled shRNA control 
cells (Figure 2.12B) and FACS analysis did not reveal a significant difference in the 
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proportion of S/G2/M-phase cells (Figure 2.12C). Likewise, no effect was observed in 
Meis1-transduced Prep1 overexpressing cells (data not shown). I conclude that Pbx1 
downregulation does not affect cell proliferation in this system. 
To study the tumorigenic potential of Pbx1 knockdown (Pbx1kd) cells, soft agar 
assays and allograft studies in nude mice were performed. The colony formation potential 
of Pbx1kd Meis1-transformed cells was substantially decreased (>69%) when compared 
with Meis1-transformed cells transduced with a scrambled shRNA vector (Figure 2.12D). 
The effect of Pbx1 knockdown was not observed in cells also overexpressing Prep1, 
whose tumorigenic activity is already lower in the presence of a scrambled vector (Figure 
2.12D). In addition, mice transplanted with Pbx1kd Meis1-transformed cells yielded 
smaller tumors compared to the control group (Figure 2.12E upper graph). Whereas Pbx1 
knockdown had essentially no effect on Meis1-transformed Pbx1kd cells overexpressing 
Prep1 (Figure 2.12E lower graph). For clarity the effect of Pbx1 downregulation on Meis1 
tumorigenicity and Prep1 tumor suppressive function has been reported in two separate 
graphs. However, the experiment was performed at the same time. 
The fact that Meis1 did not transform the Pbx1 downregulated cells as efficiently as 
control, indicates that Meis1-mediated transformation is dependent on the presence of 
Pbx1 protein and further supports the idea that not only in MLL-induced leukemia but 
also in MEFs transformation, Meis1 functions in complex with Pbx proteins [149]. The 
minor effect of Prep1 on Pbx1kd Meis1-transformed cells shows that also Prep1-inhibition 
of Meis1 tumorigenicity requires Pbx1. Thus in Prep1i/i cells, overexpression of Meis1 
induces strong tumorigenicity which is decreased by Pbx1 kock-down. Likewise, the 
inhibition of tumorigenicity by Prep1 is only slightly stimulated by Pbx1 kock-down. All 
this suggests that Meis1 and Prep1 compete for Pbx1 and hence that Pbx1 cooperates with 
an oncogene (Meis1) as well as with a tumorsuppressor (Prep1), confirming the previous 
data with Prep1ΔHR1+2 (Figure 2.6 D and E). 
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Figure 2.12. Pbx1 is required for Meis1-mediated transformation and Prep1-
inhibition of Meis1 tumorigenicity. (A, upper panel) Immunoblot represents the Pbx1 
downregulation efficiency in the nuclear lysate of Meis1a or Meis1a plus Prep1 
overexpressing Prep1i/i MEFs. Two different shRNA were used against Pbx1, namely 
shPbx1 #8 and Pbx1 #10. Nucleolin was used for protein loading control. Quantification 
of the bands was done by densitometric analysis. (A, lower panel) Immunoblots show the 
protein level of Meis1a, and Prep1 in the nuclear and cytoplasmic extracts of the Pbx1-
depleted cells compared to the control. Pbx2 protein level was only checked in the 
nuclear lysates. PCNA and vinculin were used as loading controls of nuclear and 
cytoplasmic lysates, respectively. Quantification was done by densitometry on nuclear 
lysates only. (B) 5 × 104 Pbx1kd Prep1i/i cells overexpressing Meis1a were plated in 6-well 
plates and were counted at the indicated time points. The experiment was performed in 
triplicate. Error bars indicate standard deviation. (C) DNA content analysis was 
determined by FACS analysis of Pbx1kd Prep1i/i cells overexpressing Meis1a after BrdU 
/PI staining. Asynchronously growing cells were pulse-labeled with BrdU for 45 min 
before harvesting. After fixation, cells were stained with FITC-coupled anti-BrdU 
antibody and analyzed by flow cytometry to determine BrdU incorporation and cell cycle 
distribution. Cells were stained with PI for DNA content. 1 × 106 cells were used for 
FACS analysis. The graph shows the percentage of the cells in the different phases of the 
cell cycle. Representative scatter plots with the log FITC anti-BrdU staining (FL1-H) 
versus PI staining (FL3-H) are shown. Cell cycle distribution of cells was calculated 
using the gates shown in the scatter plots: R4, G1 phase; R6, S phase; R5, G2/M phase. 
(D) Soft agar colony formation of Pbx1kd cells overexpressing Meis1a or Meis1a along 
with Prep1 is shown relative to cells transduced with scrambled lentiviral vector. 1 × 105 
cells per plate was used for each experimental points and the experiment was performed 
in triplicate. Error bars indicate standard deviations of two independent experiments. (E) 
Pbx1kd cells overexpressing Meis1a (upper panel) or coexpressing Meis1a and Prep1 
(lower panel) were subcutaneously transplanted in nude mice (1 × 106 cell per animal) 
and the tumor volume was monitored over time. Lines represent the average of five 
animals per group. For clarity SD is not shown. P < 0.05. 
 
2.13. Ddx3x and Ddx5 depletion impair cell proliferation and colony 
formation in soft agar.  
To investigate the functional relation between Ddx3x or Ddx5 and Meis1a, we 
assessed the role of Ddx3x or Ddx5 on Meis1-induced tumor formation in the Prep1i/i 
MEFs. Ddx3x or Ddx5 protein levels were respectively depleted by ~50% and ~70% in 
these cells with two independent shRNAs targeting each genes (Figure 2.13A). Ddx 
downregulation did not affect protein level of Meis1a and its partner Pbx1 (Data not 
shown). Ddx3xkd and Ddx5kd cells changed their morphology compared to the control 
cells. They became abnormally flat looking like serum-starved cells and round bodies 
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appeared that may correspond to cell carcasses (Figure 2.13B). Therefore as expected 
[194,224], Ddx downregulation severely compromised the proliferation ability of Meis1a 
transduced Prep1i/i cells (Figure 2.13C). Furthermore I studied the impact of Ddx 
depletion on Meis1 induced transformation. To this end, I measured the anchorage 
independent growth in semi-solid medium. As shown in figure 2.13D, Ddxkd cells showed 
a strong reduction in the number of colonies when plated in soft agar. Overall, these 
results indicate that both Ddx3x and Ddx5 have important roles in cell proliferation and 
their downregulation inhibits Meis1-induced transformation in vitro. 
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Figure 2.13. Impaired proliferation and transformation activity of Ddx3x or Ddx5 
depleted cells. (A) Prep1i/i cells overexpression Meis1a were treated with Ddx3x, Ddx5 
and scrambled shRNA retroviruses resulting in efficient downregulation of protein level 
of these genes as shown by western blotting. Vinculin was used as a loading control. 
Quantification of the bands was done by densitometric analysis. (B) Ddx3xkd and Ddx5kd 
cells were photographed one weeks after infection. Cells induced with scrambled shRNA 
were used as control. (C) 5 × 104 Ddxkd cells were plated in 6-well plates, fixed at the 
indicated time points, stained with 0.1% crystal violet solution and the OD 595 nm 
determined. The experiment was performed in triplicate. Error bars indicate standard 
deviation. (D) Soft agar colony formation of Ddx3xkd and Ddx5kd cells overexpressing 
Meis1a is shown relative to cells transduced with scrambled lentiviral vector. 1 × 105 cells 
per plate were used for each experimental points and the experiment was performed in 
triplicate. Error bars indicate standard deviations of two independent experiments.  
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Accumulating evidence implicates several members of the TALE protein in a 
growing number of diseases including cancer: Pbx1 in B-cell ALL [79,101], Meis1 as a 
Hoxa9 collaborating oncogene in AML induction [41,43] and Prep1 as a tumor 
suppressor in man and mouse [19]. In this thesis, I studied the oncogenic role of Meis1 in 
MEFs and its possible interaction with Prep1 to better understand the pathways affected 
by these proteins.  
 
3.1. Meis1 is a bona-fide oncogene in MEFs. 
The effect of Meis1 on proliferation and tumorigenesis had been studied in the 
context of leukemia. Although genetic signature studies of cancer have revealed the 
overexpression of Meis1 in a number of so called expression modules activated in tumors 
of lung, neural, liver, breast and prostate origin [225], so far only very few studies have 
shown the involvement of Meis1 in solid tumors [157,158]. Therefore, the effect of Meis1 
expression in non-hematological malignancies is largely unexplored. In this regard, I took 
advantage of MEFs to study the oncogenic impact of the Meis1 in non-hematic cells. 
Moreover, MEFs provide an easy model system to dissect the molecular pathways 
underlying Meis1 oncogenicity and its interactions with the tumor suppressor member of 
the TALE transcription factors, Prep1. 
I have shown that Meis1 induces cell proliferation in primary p53ko and late-passage 
Prep1i/i MEFs. In rodent fibroblasts, absence of either p53 or p16 is sufficient to inhibit 
oncogene-induced proliferation arrest. In fact, Serrano et al. [226] have shown that 
oncogenic Ras alone efficiently transforms either p53 or p16 knockout primary MEFs but 
needs a cooperating oncogene such as Myc to transform wild-type cells. Consistent with 
these observations, I show that transformation of MEFs by Meis1 requires either a 
cooperating oncogene such as Hoxa9, Ras or Myc or the inactivation of a tumor 
Discussion 
 
 
 103 
suppressor such as p53 in primary cells or Prep1 in late-passage cells. These results 
indicate that p53 and Prep1 are essential to inhibit Meis1-induced proliferation and 
subsequent transformation and that the inactivation of either p53 in primary cells or 
Prep1 in late passage MEFs alone is sufficient for the transformation.  
Longobardi et al. [19] demonstrated that Prep1 deficiency leads to spontaneous tumors in 
mice and that its haploinsufficiency accelerates lymphomagenesis in the EµMyc mice 
model. Consistent with these data, Prep1i/i MEFs are easily transformed by Meis1 alone 
as studied by soft-agar assays and tumor formation in mice. Indeed, Meis1 alone 
transforms Prep1i/i cells as efficiently as when co-expressed with Hoxa9. Colony 
formation in soft-agar indicates loss of contact inhibition and a transformed phenotype. 
Prep1i/i cells transduced with Meis1 formed colonies in soft-agar and tumors in nude 
mice. However in wild type cells, Meis1 requires the oncogene Hoxa9 to transform cells. 
Interestingly, Hoxa9 alone transforms primary bone marrow cells and Meis1 coexpression 
only accelerates leukemogenesis [41]. This shows that the oncogenic activity of 
oncogenes such as Meis1 and Hoxa9 is context and cell type dependent. Thus Meis1 is a 
bona-fide oncogene in MEFs but Hoxa9 is not. These results also show a major difference 
between Meis1 and Prep1. The former must act by stimulating the signaling pathways 
leading to cancer; whereas Prep1 acts in the opposite direction inducing cell changes that 
prevent the activity of an oncogene like Meis1. 
 
3.2. Why does Meis1 transform MEFs in the absence of Prep1?  
It appears that Prep1 mainly exerts its tumor suppressor function by maintaining 
genomic stability [179]. In early embryogenesis, Prep1 protects epiblast cells from 
accumulating DNA damage that induce apoptosis. The absence of Prep1 results in p53-
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dependent apoptosis of epiblast cells, which do not reach gastrulation and differentiation 
[168]. The role of Prep1 in maintaining genomic stability is not only limited to 
embryogenesis and epiblast cells but is also exerted in the other cell types. In MEFs and 
in the human fibroblast cell line, BJ, Prep1-deficiency leads to genetic instability shown 
by increased DNA damage response, aneuploidy and chromosomal aberrations [179]. The 
genomic instability is one of the common characteristics of cancer [27], and actually, 
mutations in genes involved in processes like DNA repair, checkpoint control, 
chromosomal segregation, and centrosome duplication have oncogenic effects [227]. 
Many tumor suppressor genes are acting by controlling these processes. The genomic 
lesions emerged in the absence of Prep1 makes cells susceptible to oncogene-induced 
transformation. 
 Since Meis1 alone is not able to transform primary Prep1i/i MEFs and since Prep1i/i 
mice which escape embryonic lethality develop tumors only later in life, my conclusion is 
that regardless of the cellular context, Prep1-deficiency over time causes the 
accumulation of genetic alterations which favor tumorigenicity. This is probably why 
Meis1 transforms late-passage and not primary Prep1i/i cells. 
Furthermore, I addressed the effect of Prep1 restoration level on Meis1-induced 
tumor formation and found that Meis1-tumorigenicity is partially rescued by Prep1 re-
expression both in vitro by growth in soft-agar and in vivo by tumor formation in nude 
mice. This suggests that Prep1 is capable of an at least partial reversal of the 
tumorigenicity. The effect of Prep1 re-expression might be important for future 
therapeutic developments since many human tumors [19] express very low levels of 
Prep1.   
Why can Prep1 level restoration not fully rescue Meis1-tumorigenic effect? Since 
genomic lesions are irreversible, Prep1 re-expression can not reverse those lesions. 
Discussion 
 
 
 105 
However, the partial rescue may identify some tumorigenic pathways not caused by 
mutations but by changes of gene expression. These maybe studied as a prosecution of 
this work as they would present tumor suppressive pathways. 
3.3. Meis1 and Prep1 compete for Pbx1 in the context of tumorigenecity. 
The first attempt to better understand the tumor suppressive function of Prep1 was 
to find the domains responsible for its tumor suppressor function. Molecular dissection of 
Prep1 revealed that the HR1+2 (Pbx-interacting) domain of Prep1 is indispensable for its 
tumor suppressive function. Indeed, the deletion of the HR1+2 domain blocked Prep1 
inhibition of anchorage-independent cell growth and tumor formation induced by Meis1. 
However, the fact that HR1+2 domain on its own is endowed with the tumor-inhibition 
activity needs to be further studied. To do so, I have generated a construct carrying only 
the HR1+2 domain of Prep1, which will be tested in the inhibition of Meis1-induced 
tumorigenicity. Both Meis1 and Prep1 interact with Pbx homeoproteins through the 
HR1+2 domain [75]. In fact, Prep1ΔHR1+2 mutant is not able to interact with Pbx1, as I 
have shown by IP, and hence cannot stabilize Pbx1 proteins. In fact, Prep1 dimerization 
with Pbx is important to prevent Pbx protesomal degradation [76]. Accordingly, the 
interaction with Pbx1 is unaffected in cells overexpressing the other domains of Prep1, 
Prep1ΔHD and Prep1ΔC mutants. These mutants interact with Pbx1 and elevate its 
protein level as shown by IP and western blotting. 
Prep1 does not have an NLS and to date it is believed that it needs to dimerize with 
Pbx1 to be translocated to the nucleus [75]. Thus, to exclude the possibility that the 
impaired tumor suppressor function of Prep1ΔHR1+2 mutant was not due to the lack of 
functional Pbx1 interaction but to its inability to translocate to the nucleus, where Meis1 
exerts its oncogenic activity, I performed IF and western blotting on the Prep1i/i cells 
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overexpressing Prep1ΔHR1+2 as well as other Prep1 mutants. Although Prep1ΔHR1+2 
cannot interact with Pbx1, it still can be detected in both nucleus and cytoplasm of the 
infected cells. The other mutants showed mainly nuclear localization, as expected. This 
indicates that Prep1 nuclear translocation is not necessarily limited to the interaction with 
Pbx1 but that also other proteins or mechanisms may be involved in this translocation. 
Several studies have shown the involvement of Meis-Pbx and Hox-Pbx interactions 
in carcinogenesis [42,228]. The ability of Meis1 to interact with Pbx proteins is essential 
for the induction and maintenance of MLL-mediated myeloid transformation. Both the 
deletion of the HR1+2 domain of Meis1 [42] or depletion of Pbx [149] abolish Meis1 
oncogenic activity. Thus MLL-mediated transformation requires Meis1 as well as Pbx 
proteins [42,149]. Moreover the oncogenic potential of Hoxa1 relies on the interaction 
with Pbx1 through the hexapeptide motif and the mutated hexapeptide motif loses the 
interaction with Pbx1 and is not able to confer oncogenic potential to Hoxa1 [228]. 
Likewise, the mutated HOXB4 hexapeptide impairs HoxB4-induced transformation [229]. 
Similarly, Fernandez et al. [230] showed that a dominant negative mutant of PBX, unable 
to bind to DNA but capable of binding Prep1, reduces the oncogenic activity of HoxB7. 
Thus the integrity of the Pbx-interacting domains of Meis1 and Hox proteins is important 
for their oncogenic activity.  
Consistent with the importance of the Meis1-Pbx interaction in MLL-mediated 
myeloid transformation [42,149], I have shown that also in MEFs Meis1 requires Pbx for 
oncogenic transformation. Indeed, Pbx1 depletion in Prep1i/i cells overexpressing Meis1 
attenuated the tumorigenic potential of these cells. The number of colonies formed in 
soft-agar and the size of the tumors in transplanted mice decreased in Pbx1-depleted cells. 
Moreover, also Prep1 was unable to rescue the residual Meis1-induced tumorigenicity in 
the Pbx1 down-regulated cells. In fact, cells co-expressing Meis1 and Prep1 showed the 
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same tumorigenic potential in Pbx1 depleted and control cells both in vitro and in vivo. 
Thus also Prep1 suppressive function requires Pbx1. Meis1 and Prep1 proteins share 60% 
sequence identity in their Pbx interacting domain and both can recruit Pbx for their 
biological functions [43,51,76]. Based on the observations that both Meis1 and Prep1 
need to interact with Pbx proteins to exert their oncogenic and oncosuppressive activities, 
respectively, I suggest that Meis1 and Prep1 compete for Pbx1 in the context of 
tumorigenesis. 
In addition to competing for Pbx1, Prep1 re-expression significantly decreases the 
endogenous and exogenous Meis1 protein level. This might well explain the smaller 
tumor size. Therefore, Prep1 can prevent Meis1 oncogenic activity by both competing for 
Pbx1 and decreasing Meis1. 
 
3.4. Meis1 interacts with Ddx3x and Ddx5 RNA helicases only in the 
absence of Prep1.  
The fact that Meis1 only transforms Prep1i/i and not wild type cells not only 
depends on the ability of Prep1 to compete for the common partner, Pbx1, but also relies 
on the loss of other interactions of Meis1. Competition for Pbx1 would be only one of the 
possible explanations for Meis1 and Prep1 opposite functions in tumorigenicity, since 
mass spectrometry analysis showed that the presence of Prep1 alters the composition of 
the Meis1 protein complex. 
In fact, I have shown that Meis1 interacts with ATP-dependent RNA helicases 
Ddx3x and Ddx5 proteins only in Prep1i/i cells. Ddx3x and Ddx5 are known to have 
oncogenic properties [191,196]. In addition, restoration of Prep1 level perturbs this 
interaction. The interaction with Ddx3x and Ddx5 is specific for Meis1, since Prep1 does 
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not interact with these proteins. IP experiments performed on the nuclear lysate of Prep1i/i 
and Prep1i/i cells re-expressing Prep1, showed that in the presence of Prep1 the 
interaction of Meis1 with Ddx3x and Ddx5 was lost.  
By molecular dissection of Meis1, I show that Ddx3x mainly binds to the 
homeodomain (DNA-binding) of Meis1 while Ddx5 interacts with both the homeodomain 
and the C-terminal domain (CTD) of Meis1. Several studies have shown that the 
homeodomain and the CTD of Meis1 contribute to its pro-tumorigenic activities 
[42,135,136,137,231]. For instance, Meis1 CTD is sufficient to transform non-oncogenic 
Prep1 into a Hoxa9 cooperating oncoprotein [137]. The CTD of Meis1 has transactivating 
properties which are missing or different in Prep1. Meis1 and a chimeric Meis1-Prep1 
regulate an overlapping set of genes implicated in control of cellular proliferation and 
division, showing that the leukemogenic potential of Meis1 relies on its ability to 
deregulate multiple pathways [137]. Thus the interaction of Meis1 with Ddx3x and Ddx5 
might have an important impact on Meis1-induced oncogenicity. 
Overall, my data on one hand show that Meis1-induced tumor formation is much 
more complex than a simple Meis1-Pbx interaction and on the other hand demonstrate 
that Prep1 may employ a broad range of ways to suppress Meis1 oncogenicity; at least 
competition for Pbx, interaction with the RNA helicases and control of Meis1 gene 
expression. 
 
3.4.1. What is the role of Ddx RNA-helicases in Meis1-induced 
transformation? 
DEAD-box proteins are the largest RNA helicase family, with 38 members in man 
that are associated with almost all processes involving RNA, including ribosome 
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biogenesis, transcription, pre-mRNA splicing, RNA maturation, RNA export, translation 
and RNA decay [181,182]. Multiple studies have shown overexpression of some 
members of the DEAD-box family in tumor cell lines and tumor tissues. Some of them 
are also known to be implicated in DNA repair and cell growth control. Thus, DEAD-box 
proteins have potentially important roles in cancer development [203].  
DDX3X (DDX3 or DBX) is a member of the human DEAD-box family of RNA 
helicases, first identified in 1997 as one of the five genes on the X-chromosome which 
have homologs in the non-recombining region of the Y-chromosome (DDX3Y or DBY). It 
escapes X-inactivation and is ubiquitously expressed in a broad range of tissues [232]. As 
depicted in Figure 3.1, DDX3X has been involved in all processes regulating gene 
expression, including transcription, pre-mRNA splicing, RNA export and translation. 
Furthermore, it has also been implicated in cell cycle control and apoptosis regulation. 
Interestingly, a great deal of research has focused on DDX3X because of its role in the 
replication of HCV, HIV and poxviruses [195,232]. Ddx5 is one of the prototypic 
members of the DEAD-Box family of RNA helicases. Like DDX3X, it functions in the 
entire process of gene expression and RNA metabolism [203].  
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Figure 3.1. DDX3 involvement at different stage of gene expression regulation. (A) 
DDX3 interacts with splicing factors and Ribonucleoproteins (RNPs). (B) CRM1 and 
TAP export shuttle export DDX3 from the nucleolus. (C) DDX3 is involved in the 
regulation of translation. (D) DDX3 is implicated in the transcriptional regulation of 
different genes (see the text for more information) [232]. 
 
Thus one of the common and at the same time interesting functions of these two 
proteins is their involvement in transcription and cell cycle regulation. They interact with 
different transcription factors and act as transcriptional coactivators/corepressors. 
DDX3X is recruited to specific promoters. It binds to Sp1 transcription factor and 
increases the expression of p21WAF. It also has been shown to bind to the E-Cadherin 
and IFNβ promoters, to upregulate IFNβ and downregulate E-Cadherin expression 
(Figure 3.1) [232]. How DDX3 is recruited to the promoters is still unknown. DDX3 was 
first suggested to have a leucine-zipper motif but there is no evidence that it can bind to 
specific DNA sequences. Thus, more likely DDX3 recruitment to specific promoters 
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takes place through interaction with promoter-specific transcription factors or other 
coactivators as shown for the p21waf promoter [232]. DDX5 can act both as a 
transcriptional coactivator interacting with CBP, p300, SRC1 and RNA polymerase II, as 
well as a transcriptional corepressor by interacting with HDAC1 [203]. It would be 
interesting to identify Ddx3x and Ddx5 target genes by ChIPseq, an experiment that 
might be done in the near future. 
Consistent with the above data, Meis1 might recruit Ddx3x and Ddx5 to the 
regulatory regions of its target genes or sequester them preventing the interaction with 
other genes. In fact, DDX5 can bridge transcription factors, coactivators and RNA 
polymerase II [203]. In turn, these proteins might bridge Meis1 to other transcriptional 
regulators and control Meis1-dependent gene expression acting like bona fide 
transcription activators or repressors. Likewise, their absence from specific regulatory 
sites may have important transcriptional consequences. The impairment of Meis1 
interaction with Ddx proteins suggests their importance for Meis1-dependent gene 
expression. However, the impact of the Ddx3x and Ddx5 on Meis1 transcriptional activity 
still requires to be assessed.  
The involvement of Ddx5 and its close homologue Ddx17 in the regulation of 
oncogenes such as c-Myc, Cyclin D1, Fra-1, and c-jun suggests that they could have an 
impact on cell proliferation [207]. In the developing zebrafish eye, Meis1 controls the 
proliferation of multipotent cells by regulating Cyclin D1 and c-Myc expression [233] and 
in leukemogenesis cyclin D3 is a direct downstream target of Meis1 [135]. These data 
provide a link between Ddx proteins and Meis1 in proliferation and cell cycle control in 
both development and tumorigenesis.  
I tried to downregulate either Ddx3x or Ddx5 in Prep1i/i cells overexpressing Meis1. 
However, this procedure severely impaired cells proliferation (Figure 2.13C). The cells 
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lost their anchorage independent-growth capacity, as also shown by Shin et al. [207] in 
colon cancer cells. This has so far prevented me from examining the direct responsibility 
of Ddx proteins in Meis1 tumorigenesis. Ddx5 and Ddx17 are overexpressed in colon 
cancer and their downregulation in colon strongly compromises the ability of the cells to 
proliferate and form tumors in mice [207]. Overexpression of these proteins correlates 
with the progression of the disease from polyp to adenoma to adenocarcinoma [207]. 
However, in the present study, Ddx3x and Ddx5 protein level did not change in the Meis1 
overexpressing cells. However, it is known that Ddx5 stability might be 
posttranslationally modified in cancer cells by tyrosine phosphorylation or ubiquitylation 
[213,214]. At this stage the hypothesis can be made that Meis1 complexes with Ddx3x 
and Ddx5 transform cells by activating the expression of genes involved in cell 
proliferation. As a result, impairment of this complex (for example by Prep1), reduces 
Meis1 ability to activate cell proliferation, suppressing Meis1-induced tumorigenesis. 
This hypothesis can be experimentally verified.  
 
3.5. Final Remarks 
The TALE family of transcription factors is a very complex family within the 
homeodomain transcription factors superfamily. PBC and MEIS subfamilies are both 
structurally and functionally related with a wide range of common targets and/or 
functions not only in development but also in diseases including cancer. However the 
mechanisms underlying their functions are mainly unknown. The facts that two closely 
related members of the MEIS subfamily, Meis1 and Prep1, exert opposite roles in 
carcinogenesis, indicates that their cross-modulation can affect multiple cellular 
pathways. The data presented in the present thesis will be helpful to understand the role of 
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TALE proteins in cancer; however a great deal of further research is required to elucidate 
the affected pathway and how they are misregulated. 
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4.1. Buffers and Solutions 
4.1.1. Phosphate-Buffered Saline (PBS)  
NaCl  
KCl  
KH2PO4 
Na2HPO4 × 7H2O 
137 mM 
2.7 mM 
1.47 mM 
8.0 mM 
To prepare 1 liter of 10X PBS 80 g of Nacl, 2 g of KCl, 21.6 g of Na2HPO4 × 7H2O 
and 2g of KH2PO4 were solved in 800 mL of distilled water. The pH was adjusted to 7.4 
with HCl. 
 
4.1.2 Tris-Buffered Saline (TBS)  
NaCl  
KCl  
Tris HCl pH 8.0 
150 mM 
2.7 mM 
25 mM 
To prepare 1 liter of 10X TBS, 80 g of NaCl, 30 g of Tris base and 2 g of KCl was 
dissolved in 800 mL of distilled H2O and the pH was adjusted to 8.0 with HCl. 
 
4.1.3. TBST 
TBS 
Tween 20 
1X 
0.1% (v/v) 
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4.1.4. Tris-Acetate-EDTA (TAE) 50X 
Tris base                        
Glacial acetic acid              
EDTA, pH 8                      
2 M 
1 M 
10 mM 
To prepare 1 liter of 50X TAE, 242 g of Tris base, 57.1 mL of Glacial acetic acid 
and 20 mL of EDTA (0.5 M, pH 8.0) were dissolved in 800 mL of distilled H2O and pH 
was adjusted to 8.3 with Glacial acetic acid. 
 
4.1.5. Tris EDTA (TE) 10X 
Tris        
EDTA    
100 mM 
10 mM 
The pH was adjusted to 7.5 with HCl. To prepare 1 liter of 10X TE, 12.1 g of Tris, 
20 mL of EDTA and 4.2 mL of HCl were used. 
 
4.1.6. Tris-HCl 1M 
121.1 g of Tris-base is dissolved in 800 mL of distilled H2O. The pH is adjusted 
either to 7.4, 7.6 or 8.0 with HCl. The volume was adjusted to 1 liter by adding distilled 
H2O. 
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4.1.7. HBS 2X 
Hepes                         
KCl                            
Dextrose                     
NaCl                           
Na2HPO4 × 7H2O        
50 mM 
10 mM 
12 mM 
280 mM 
1.5 mM 
 
The pH was adjusted to 7.05 and solution was passed through 0.22 µm filter and 
stored at -20 °C. 
 
4.1.8. SDS-PAGE Running Buffer 10X  
Tris  
Glycine                   
SDS                        
250 mM 
192 mM 
1% (w/v) 
To prepare 1 liter of 10X running buffer, 30 g of Tris base, 144 g of Glycine and 50 
mL of 20% SDS were used. 
 
4.1.9. Western Transfer Buffer 10X 
Tris HCl pH 8.3      
Glycine                  
250 mM 
192 mM 
To prepare 1X transfer buffer, the 10X stock is diluted 1 to 10 with distilled H2O 
and Methanol or Ethanol was added up to 20% (v/v). 
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4.1.10. Laemmli Buffer 4X 
Tris HCl pH 6.8  
SDS                             
Glycerol                       
Bromophenol Blue      
200 mM 
8% (v/v) 
40% (v/v) 
0.01% (w/v) 
 
4.1.11. Ponceau Solution 
Ponceau                         
Glacial acetic acid        
0.1% (w/v) 
5% (v/v) 
 
4.1.12. Coomassie Brilliant Blue Stain 
Coomassie brilliant blue R-250     
Glacial acetic acid                          
Ethanol                                          
0.2% (w/v) 
10% (v/v) 
30% (v/v) 
 
4.1.13. Coomassie De-Staining Solution 
Glacial acetic acid                        
Ethanol                                        
10% (v/v) 
30% (v/v) 
 
4.1.14. Proteinase K Lysis Buffer (PKLB) 
Tris-HCl pH 8.5         
EDTA                         
100 mM 
5 mM 
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SDS  
NaCl  
Proteinase K 
0.2% (v/v) 
200 mM 
100 µg/mL 
 
4.2. Reagents 
4.2.1. Primary Antibodies 
 
Antibody Type Product Code Dilution Use 
Prep1 
CH12.2 
Mouse-
monoclonal 
Home made 1 µg/mL WB 
Prep1 Rabbit-
polyclonal 
Santa Cruz sc-6245 1 µg/mL WB/IF 
Meis1 K845 Rabbit-
polyclonal 
Provided by Miguel Torres 1 µg/mL WB 
Pbx1 Rabbit-
polyclonal 
Santa Cruz sc-889X 1 µg/mL WB 
Pbx1b Mouse-
monoclonal 
Provided by Micheal Cleary 2 µg/mL WB 
Pbx2 Rabbit-
polyclonal 
Santa Cruz sc-890 1 µg/mL WB 
Ddx5 Goat-
polyclonal 
Abcam ab10261 1:2000 WB 
Ddx3X Rabbit-
polyclonal 
Millipore NG1895575 1:1000 WB 
FLAG 
Clone M2 
Mouse-
monoclonal 
Sigma F3165-5MG 1:5000 WB 
Nucleolin Rabbit-
polyclonal 
Novus Biologicals NB600-
241A1 
1:4000 WB 
Vinculin Mouse-
monoclonal 
Sigma V9B1-o.5ML 1:10000 WB 
Hoxa9 Rabbit-
polyclonal 
Upstate 07-178 2 µg/mL WB 
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PCNA Mouse-
monoclonal 
Abcam ab29-100 1:1000 WB 
Ras Mouse-
monoclonal 
BD Transduction    
labratoriesTM  
610002 
1:500 WB 
c-Myc Rabbit-
polyclonal 
Santa Cruz sc-764 1:200 WB 
PCNA Mouse-
monoclonal 
Abcam ab29-100 1:1000 WB  
4.2.2. Secondary Antibodies 
 
Antibody Product Code Dilution Use 
Goat polyclonal anti-Mouse IgG-
HRP (H+L)  
Biorad          
(170-6516) 
1:10000 WB 
Goat polyclonal anti-Rabbit IgG-
HRP (H+L)  
Biorad          
(170-6515) 
1:10000 WB 
Rabbit polyclonal anti-Goat IgG-
HRP (H+L)  
Dako     
(P044902)  
1:3500 WB 
Alexa Fluor 647 Donkey anti-
rabbit IgG (H+L)  
Invitrogen 
(A31373)  
1:100 of 2 mg/mL 
stock  
IF 
 
4.2.3. shRNA Lentiviral Vectors 
Sequence-verified MISSION shRNA lentiviral plasmids (pLKO.1-puro) were 
purchased from Sigma to downregulate Ddx3x, Ddx5 and Pbx1 genes expression.  
 
Target gene TRC number shRNA sequence 
Ddx5 
(NM_007840) 
TRCN000007
1103 
CCGGCGGGAAGCTAATCAAGCAATTCTCGA
GAATTGCTTGATTAGCTTCCCGTTTTTG 
Ddx5 
(NM_007840) 
TRCN000007
1104 
CCGGGCGAATGTCATGGATGTGATTCTCGA
GAATCACATCCATGACATTCGCTTTTTG 
Matherials and Methods 
 
 
 121 
Ddx3x 
(NM_010028) 
TRCN000010
3750 
CCGGGCTGTGATTCTCCACTGAAATCTCGA
GATTTCAGTGGAGAATCACAGCTTTTTG 
Ddx3x 
(NM_010028) 
TRCN000010
3751 
CCGGCCGTGATTTCTTAGATGAGTACTCGA
GTACTCATCTAAGAAATCACGGTTTTTG 
Pbx1 #8 
(NM_008783)  
TRCN000001
2575 
CCGGGCCTGCCTTGTTTAATGTGTTCTCGA
GAACACATTAAACAAGGCAGGCTTTTT 
Pbx1 #10 
(NM_008783) 
TRCN000001
2577 
CCGGCTCACAGATCAGACAAATCTACTCGA
GTAGATTTGTCTGATCTGTGAGTTTTT 
SHC002 Mission 
non-Target 
shRNA control 
vector 
TRC1/1.5 CCGGCAACAAGATGAAGAGCACCAACTCG
AGTTGGTGCTCTTCATCTTGTTGTTTTT 
 
4.3. Cloning Techniques and Plasmids 
4.3.1. Agarose Gel Electrophoresis 
DNA samples (either PCR products or digested DNA fragments) were loaded onto 
0.8% - 2% agarose gel prepared in 1X TAE buffer containing 1X Gel Red (from 
Biotium). Electrophoresis was carried out at 80 V. The DNA bands were visualized under 
UV light exposure. 1 kb or 100 bp DNA ladders (from promega) were used as molecular 
size standard. 
 
4.3.2. Bacterial Transformation and Plasmid Mini-Preparation 
One Shot® TOP10 chemically competent E.coli (Invitrogen™ Cat No. C4040-06) 
was used for transformation. For each reaction 1 vial of competent bacteria was thawed 
on ice. 1 to 5 µL of plasmid DNA (10 pg to 100 ng) was gently mixed with bacteria and 
incubated on ice for 30 min. Cells were heat-shocked for 40 sec at 42 °C and placed on 
ice for 2 min. 250 µL of pre-warmed S.O.C. Medium was added to each vial aseptically 
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and shake horizontally at 37°C for 1 hour at 225 rpm in a shaking incubator. 20 - 200 µL 
from each transformation was spread on a pre-warmed LB agar plates supplemented with 
100 µg/mL ampicillin and incubated overnight at 37 °C. Single bacterial colonies were 
picked and cultured in overnight 10 mL LB supplemented with 100 µg/mL ampicillin. 
Plasmid DNA was extracted from the bacterial pellet of overnight culture using Wizard® 
Plus SV Minipreps DNA Purification System (Promega Cat.No. A1465). The accuracy of 
the cloned fragments was check by sequencing. 
 
4.3.3. Plasmid Maxi-Preparation 
Plasmid DNA was isolated from 250 mL of overnight bacterial culture in LB broth 
supplemented with 100 µg/mL ampicillin using QIAGEN Plasmid Maxi Kit (QIAGEN 
Cat.No. 12163). 
 
4.3.4. Retroviral Expression Vectors 
Prep1 deletion mutants have been described [73]. They carry the following 
modifications: a) deletion of the Pbx interacting domain (Prep1ΔHR1+2, deleted 
residues: 58-137); b) deletion of the DNA binding homeodomain (Prep1ΔHD, deleted 
residues: 259-318). The mutants were amplified from the original vector using primers 
listed in the following table and were cloned in pMSCV-hygro vector along with FALG-
tag. 
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Primers set Sequences (5ʹ′→3ʹ′) 
 
Prep1-XhoI-FLAG-Fwd 
Prep1-XhoI-Rev 
cgcCTCGAGATGGACTACAAGGACGACGATGACAAG
ATGATGGCTACACAGACATTAAG  
 
cgcCTCGAGCTACTGCAGGGAGTCACTGTTC 
 
 
 
Prep1ΔC construct was generated by deletion the C-terminal domain of the protein 
(residues: 318-436). cDNA pool from MEFs was used as template for the PCR reaction. 
Phusion high fidelity DNA polymerase (FINNZYMES Cat.No. F530S) was used in 
PCR reactions to amplify Prep1ΔC fragment. This fragment was cloned in pMSCV-hygro 
vector along with FALG-tag. The primers used for this cloning are listed below. 
 
Primers set Sequences (5ʹ′→3ʹ′) 
 
Prep1-XhoI-Flag-Fwd 
Prep1-XhoI-Rev 
cgcCTCGAGATGGACTACAAGGACGACGATGACAAGAT
GATGGCTACACAGACATTAAG  
 
cgcCTCGAGTTACATTGGCTGAAGAATTGGTC   
 
Other retroviral vectors used in this study are listed in the table below: 
 
Vector Tag Insert Species Cloning site Selection 
markers 
pMSCV FLAG Meis1 Mouse BglII/XhoI Puromycin 
MigRI FLAG Prep1 Human XhoI GFP 
pBabe  Myc Mouse  Hygromycin 
pBabe  Prep1 Human SnaBI/SalI Puromycin 
pBabe  H-Rasv12 Human  Hygromycin 
pBabe  H-Rasv12 Human  Puromycin 
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4.3.5. TAP-Meis1a Construct 
To construct Meis1a-TAP vector, seamless gene fusion technique by overlap PCR 
was used [234]. TAP cassette which contains a calmodulin binding peptide (CBP), a TEV 
cleavage sequence, and two protein A (ProtA) modules, was amplified using pBabe–
Prep1-TAP vector as template [223]. The Meis1a and TAP cassette fragments are PCR 
products amplified individually so that the end of Meis1a reverse primer has 15 bases 
complementary to the TAP cassette forward primer. cDNA pool from MEFs was used to 
amplify Meis1a cDNA. The PCR products were then used as templates for a second PCR 
amplification with Meis1a forward and TAP cassette reverse primers. To facilitate 
efficient PCR amplification, a similar melting temperature (Tm) used for all primers in 
the range of 57 °C to 61 °C. Gel purified Meis1a-TAP fusion fragments were digested 
with XhoI-HpaI restriction enzymes and cloned in pMSCV-puro retroviral vector. Some 
positive clones were sequenced to verify the sequence of the fusion fragment. The sets of 
primers used for this cloning are listed below. 
Primers sets Sequences (5´→3´) 
Meis1a Forward Primer  
Meis1a Reverse Primer + TAP overlap 
sequence 
 
TAP cassette Forward Primer  
 
TAP cassette Reverse Primer  
ATGGCGCAAAGGTACGACGAC   
CTTCTCTTTTCCATTTGCATGTAGTGCC
ACTGC 
 
ATGGAAAAGAGAAGATGGAAAAAGAA
TTTC 
TCAGGTTGACTTCCCCGCG 
4.3.6. Plasmids Used in Pull-Down Assay 
4.3.6.1. pGEX-Meis1a Mutant Constructs 
Meis1a, Meis1a-Nter (residues: 1-266), Meis1a-HD+Cter (residues: 267-390), 
Meis1a-HD (residues: 267-338) and Meis1a-Cter (residues: 339-390) fragments were 
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amplified using primers listed below and cDNA pool prepared from MEFs as template. 
The amplified fragments were digested by EcoRI-XhoI double digestion and gel purified. 
The digested fragments were cloned in frame with the glutathione S-transferase (GST) of 
pGEX-6p-1 vector (from GE Healthcare). The ligation products were transformed in One 
Shot® TOP10 competent E.coli bacteria (Invitrogen™ Cat No. C4040-06) and positive 
clones were verified by sequencing.  
 
Primers sets Forward Primers (5´→3´)                     Reverse Primers (5´→3´)  
Meis1a 
 
Meis1a-Nter 
 
Meis1a-
HD+Cter 
 
Meis1a-HD 
 
Meis1a-Cter 
ATGGCGCAAAGGTACGACGAC    TTACATGTAGTGCCACTGCC 
 
ATGGCGCAAAGGTACGACGAC    AGGGTCATCATCGTCACCTGTG      
 
GATAAGGACAAAAAGCGTCAC    TTACATGTAGTGCCACTGCC 
 
 
GATAAGGACAAAAAGCGTCAC    GGACTGGTCTATCATGGGC 
 
AACCGAGCAGTCAGCCAAG          TTACATGTAGTGCCACTGCC 
 
4.4. Cell Culture 
4.4.1. Isolation and Culturing of Primary MEFs 
To obtain primary Mouse Embryonic Fibroblasts (MEFs), either Prep1+/i [171] or 
p53+/- (Jackson Labs, Bar Harbor, ME, USA) animals were mated. Mice were sacrificed 
by carbon monoxide inhalation at 14.5 d.p.c. and embryos were collected in 50 mL falcon 
tubes containing ice cold PBS. Under the dissecting microscope, embryos were dissected 
from the yolk sac. Head and liver were removed. Yolk sac and head were used for 
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genotyping as described in section 4.4.2. Embryos were carefully minced with a sterile 
scalpel blade. 6 mL of DMEM medium supplemented with 10% fetal bovine serum North 
American (TET system approved from PAA laboratories), 0.1 mg/mL gentamicin 
(GIBCO™ Gentamicin Reagent Solution (50 mg/mL) liquid from Invitrogen Cat.No. 
15750060), 100 units/mL penicillin (Euroclone), 100 g/mL stereptomycin (Euroclone), 2 
mM L-glutamin (Euroclone); were added to the 6 cm Petri dish containing minced 
embryo. The tissue/medium was passed through the 2 mL syringe with 22 g needle 
several times and maintained at 37 °C, in a humidified incubator with 3% O2 and 5% 
CO2. The medium was changed every day. MEF p0 cells were split (1:3) when the cells 
were 80% confluent and some cells were frozen in freezing medium containing 
FBS+10% dimethylsulfoxyde (DMSO). MEFs in culture were split every 2-3 days and 
were used for experiments between passages 2 and 5. 
 
4.4.2. Genotyping of Prep1i/i and p53ko Mice 
Tail and yolk sac of the dissected embryos were lysed in 500 µL of PKLB at 55 °C 
for 3 hours. Proteinase K was inactivated by incubating at 95 °C for 5 minutes. 5 µL of 
the digestion product was used for genotyping with primers as previously described for 
Prep1i/i mice genotyping [171]. For Prep1i/i genotyping, the PCR was performed in 50 µL 
reaction composed of 5 µL of 5X PCR buffer (GoTaq® Felxi DNA polymerase, 
Promega), 3 mM MgCl2, 0.1 mM dNTPs, 0.25 µM of each primer and 0.025 units Taq 
Polymerase. PCR was carried out on GeneAmp PCR System 2400 (Perkin Elmer), using 
a pre-PCR step of 10 min at 94 °C, followed by 35 cycles of 15 sec at 94 °C, 15 sec at 55 
°C and 30 sec at 72 °C. Followed with the final extension for 10 minutes at 72 °C. 
Primers set used to genotype Prep1i/i embryos are listed in the table below. 
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Primers sets Sequences (5´→3´) 
Prep1F1 
Prep1R1 
LTR2  
CCAAGGGCAGTAAGAGAAGCTCTGGAG  
GGAGTGCCAACCATGTTAAGAAGTCCC 
AAAATGGCGTTACTTAAGCTAGCTTGC 
 
To genotype p53ko mice, the PCR was performed in 50 µL reaction composed of 5 µL of 
5X PCR buffer (GoTaq® Felxi DNA polymerase, Promega), 3 mM MgCl2, 0.1 mM 
dNTPs, 2 µL of primer trimix and 0.04 units Taq Polymerase. Primer trimix for p53 is 
made of 16 µL of 53/93 (25 µM), 16 µL of WT92 (25 µM) and 32 µL of KO94 (25 µM) 
primers in a final volume of 200 µL in water. The final concentration of the primers in the 
trimix is 2 µM except for KO94 that is 4 µM. The cycling was carried out with 1 cycle of 
10 minutes at 94 °C; 35 cycles of 30 sec at 94 °C, 30 sec at 55 °C and 1 minute at 72 °C. 
A final extension step was performed for 5 minutes at 72 °C. 
Primers sets Sequences (5´→3´) 
P53/93 
P53WT92 
P53KO94 
GGATGGTGGTATACTCAGAGC 
AGCGTGGTGGTACCTTATGAGC 
GCTATCAGGACATAGCGTTGG 
 
4.4.3. Immortalization of MEFs Using 3T3 Protocol 
To immortalize MEFs, 3T3 protocol was used. For serial 3T3 cultivation, WT and 
Prep1i/i primary MEFs were maintained on a defined 3 day schedule by plating 3 × 105 
cells in 60-mm Petri dishes. Cells were kept under low oxygen tension (3%) during the 
entire immortalization steps. Immortalized subclones were expanded and were used for 
the experiments. 
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4.4.4. Calcium Phosphate Transfection  
48 hours prior to the transfection, ecotropic Phoenix packaging cells were plated at 
density of 1.8 × 106 cells per 10 cm plates filled with DMEM medium supplemented with 
10% FBS-NA and 1% Glutamine. Cells were 70-80% confluent at the time of 
transfection. To perform transfection:  
- 10 µg of plasmid DNA 
- 61 µL of 2M CaCl2    
- ddH2O up to 500 µL 
were mixed thoroughly and added to 500 µL of 2X HBS (Hepes Buffered Saline) in a 
dropwise manner and kept for 10 minutes at room temperature to allow the formation of 
fine precipitates between calcium ions and DNA phosphate groups. Cells were treated 
with Cloroquine at a final concentration of 20 µM for 10 minutes. The prepared 
transfection solution was gently added to the plates and incubated at 37 °C. 8 hours post 
transfection the medium was replaced with 10 mL of fresh supplemented DMEM. The 
day after, medium was replaced with 5.5 mL of fresh supplemented DMEM in order to 
concentrate viral supernatant.  
 
4.4.5. Retroviral Infection 
MEFs target cells were plated 24 hour prior to the infection to reach 50% 
confluence by the time of infection. The viral supernatant were collected from Pheonix 
packaging cells and filtered with 0.45 µm filter and added to the target cells in the 
presence of 8 µg/mL polybrene (Hexadimethrine bromide Sigma). After 3 to 4 hours of 
incubation, a second run of infection was performed with the fresh viral supernatant for 
the next 3 to 4 hours. The day after, cells were further infected with 3rd and 4th runs of 
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infection. 48 hours after 1st run of infection, cells were either sorted for GFP expression 
or selected for puromycin dehydrochloride  (2 µg/mL, PAA laboratories) or hygromycin 
B (100 µg/mL, invitrogen) antibiotics resistance for 4 and 8 days, respectively. 
 
4.4.6. Lentiviral Infection 
5 × 106 HEK-293T helper cells per 10 cm Petri dish were plated at the day of 
transfection. Cells were transfected with 10 µg of the shRNA constructs together with the 
plasmids required for the production of viral capsid proteins following the calcium 
phosphate transfection method (section 4.4.4): 
- ENV (VSV-G)           
- PRE (gag & pol)        
- REV                           
2.8 µg 
5 µg 
2.5 µg 
48 hours after transfection, supernatant was collected and filtered with 0.45 µm filter. 
Polybrene (8 µg/mL) was added to the supernatant and cells were incubated with the viral 
supernatant for 3 hours. 2nd run of infection was performed with the fresh viral 
supernatant overnight. 48 hours post infection, cells were selected with puromycin (2 
µg/mL) for 4 days. 
 
4.5. Cell Lysis and Western Blotting  
4.5.1. Total Protein Extraction 
Culture medium was removed and cells were washed with ice cold PBS. Cells were 
scraped and collected in a falcon tube. RIPA buffer (Tris HCL pH8 50mM, Nacl 150mM, 
SDS 0.1%, Na.Deoxycholate 0.5%, Triton X-100 or NP40 1% and protease inhibitor 
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cocktail 1x (from Roche)) was added to the pellet of the cells. 300 µL of RIPA buffer was 
used to lyse around 3 to 4 × 106 cells. Cells in RIPA buffer were kept on ice for 5 min, 
pipeting up and down occasionally. Lysates were centrifuged at 13000 rpm for 15 min at 
4°C to pellet the cell debris. Supernatants were transferred to a new microtube and protein 
concentration was measured by Bradford assay (Biorad), following manufacture 
instructions. 60 µg of total extracts were used for western blotting analysis. 
 
4.5.2. Nuclear and Cytoplasmic Protein Extraction 
Cells were lysed to obtain nuclear and cytoplasmic fractions [235]. 100 µL or 300 
µL of buffer A (10 mM HEPES KOH pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT 
plus a cocktail of protease inhibitors) were used to suspend cells collected from 6 cm or 
10 cm Petri dishes respectively and incubated on ice for 10 min. 1/30 of the volume of 
10% Triton X-100 were added to the cell extract and were vortex for 30 seconds. Then 
cell extracts were centrifuged for 1 min at 11000 rpm. The resulting nuclear pellet was 
treated with 1/5 of the volume of buffer C (20 mM HEPES pH 7.8, 25% glycerol, 420 
mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA plus protease inhibitors) for 30 min at 4°C and 
centrifuged at 13000 rpm for 15 min. The supernatant was the nuclear fraction. The 
cytoplasmic fraction was treated with 0.11 volume of buffer B (0.3 M HEPES, pH 7.9, 
1.4 M KCl, 30 mM MgCl2), rotated for 30 min at 4°C and centrifuged for 15 min at 
13000 rpm. 30 µg of Nuclear and 60 µg of cytoplasmic extracts were used for western 
blotting analysis. 
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4.5.3. SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Proteins were resolved on polyacrylamide gels prepared from 30% of stock 
solutions with a ratio Acrylamide/Bisacrylamide of 29:1 (EuroClone, EMR069250). 10% 
ammonium persulphate (APS) and TEMED (EuroClone, EMR228100) were used as 
polymerization catalysts. Indicated amount of proteins were mixed with 4X sample buffer 
prior to the use and boiled at 95°C for 5 minutes. Samples loaded onto 1-1.5mm thick 
SDS-PAGE gels were run in running buffer at 25-35 mA (Biorad). 
Separating gel 
components 
Gel % 
 6% 7.5% 8% 10% 12% 
ddH2O (mL) 5.3 4.9 4.6 4 3.3 
30% acrylamide mix (mL) 2 2.7 2.7 3.3 4 
1.5 M Tris HCl pH8.8 (mL) 2.5 2.5 2.5 2.5 2.5 
10% SDS (mL) 0.1 0.1 0.1 0.1 0.1 
10% APS (mL) 0.1 0.1 0.1 0.1 0.1 
TEMED (mL) 0.008 0.007 0.006 0.004 0.004 
Total (mL) 10 10 10 10 10 
 
 
 
 
 
 
 
Stacking gel components 5% gel 
ddH2O (mL) 6.8 
30% acrylamide mix (mL) 1.7 
1.5 M Tris HCl pH6.8 (mL) 1.25 
10% SDS (mL) 0.1 
10% APS (mL) 0.1 
TEMED (mL) 0.01 
Total (mL) 10 
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4.5.4. Western Blotting 
Proteins were transferred to the nitrocellulose transfer membranes (PORTRAN®, 
pore size 0.45 µm) in western transfer tanks (Biorad) filled with 1X transfer buffer at 300 
mA for 90 minutes or at 30 mA overnight at 4°C. At the end of the transfer, membranes 
were stained with Ponceau solution to get rough estimation of the amount of the 
transferred proteins on the membranes and quality of the transferring procedure. 
Membranes were briefly washed in TBS + 0.1% Tween (TBS-T) and blocked in 5% dry 
milk in TBST for 1 hour at room temperature. Membranes then were incubated with 
primary antibodies, diluted in TBS-T 5% dry milk overnight at 4°C, followed by three 
washes of 10 minutes each with TBST-T. Membranes were then incubated with the 
appropriate horseradish peroxidase conjugated secondary antibody diluted in 5% dry milk 
in TBS-T for 1 hour at room temperature. The membranes were washed as already 
indicated and peroxidase activity was measured using the ECL methods (Amersham). In 
case of need to re-blot the membranes, they were stripped using Scientific Restore 
Stripping Buffer (Thermo Scientific Cat.No.21059) according to the manufactures 
instructions and after blocking with 5% dry milk in TBST, immunoblotted with desired 
antibodies. All densitometric analysis was performed using ImageJ software. 
4.6. Co-Immunoprecipitation  
Cells were subjected to nuclear/cytoplasmic protein extraction protocol according to 
the standard protocol (see section 4.5.2). 500 µg of nuclear lysate were used for each 
single immunoprecipitation reaction. The ANTI-FLAG M2 Magnetic Beads (Sigma 
Cat.No. M8823) were used for co-immunoprecipitations. 40 µL of the 50% bead 
suspension (∼ 20 µL of packed gel volume) was used per reaction. The packed gel was 
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washed twice with 10 packed gel volumes of TBS buffer. Indicated amount of nuclear 
lysate was added to the washed resin beads. The final volume was adjusted to 1 mL by 
adding IgG binding buffer (IBB buffer: 10 mM Tris-HCl pH 8, 0.2% NP-40, 150 mM 
NaCl). As a negative control, lysate from not infected cells were used. All samples were 
gently rotated overnight at 4 °C. The tubes were placed in the appropriate magnetic 
separator and supernatant was removed. The resins were washed 3 times with 1 mL TBS 
each time, rotating at 4 °C for the total of 45 minutes. FLAG fusion proteins were eluted 
from the beads with either one of methods mentioned below: 
- Protein elution under native condition by competition with FLAG® peptide 
(Sigma Cat.No. F3290). 50 µL of a working concentration of 100 µg/mL of FLAG 
peptide was used for elution. 
- Elution under acidic conditions with 0.1 M glycine HCl, pH 3.0. 50 µL of 0.1 M 
glycine HCl, pH 3.0 was added to each sample and control resin and incubated for 
5 minutes at room temperature. Tubes were placed in the appropriate magnetic 
separator and supernatants were transferred to fresh tubes containing 10 µL of 0.5 
M Tris HCl, pH 7.4 with 1.5 M NaCl. The IP eluates along with 50 µg of input 
lysate/each sample were loaded on an 8% SDS-PAGE and proceed to 
immunoblotting using appropriate antibodies. 
4.7. Tandem Affinity Purification (TAP) of Meis1a Interactome 
4.7.1. TAP protocol 
 TAP is a two-step affinity purification protocol to isolate TAP-tagged proteins 
together with associated proteins. To isolate Meis1a interacting proteins, cell pellet 
collected from 15 × 15 cm Petri dishes were subjected to nuclear/cytoplasmic protein 
extraction. Nuclear fractions were adjusted to the IgG binding conditions (IBB buffer: 10 
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mM Tris-HCl pH 8, 0.2% NP-40, 150 mM NaCl), incubated in batch with 100 µL of IgG 
sepharose 6 fast low beads (GE Healthcare, Cat.No. 17-0969-01) and rotated overnight at 
4°C. After washing three times with 10 mL of IBB buffer and once with 10 mL of TEV 
Cleavage Buffer (TCB: 10 mM Tris-HCl pH 8, 150 mM NaCl, 0.2% NP-40, 0.5 mM 
EDTA, 0.5 mM DTT), TEV cleavage was performed by incubation with 1 mL of TCB 
and 1.5 µL of TEV protease (5.75 mg/ mL) (Antibody and protein facility, IFOM-IEO 
campus), for 1 h at room temperature, rotating. For each milliliter of TEV eluate, 4 µL of 
1 M CaCl2 and three volumes of calmodulin-binding buffer CBB (50 mM Tris-HCl pH 8, 
150 mM NaCl, 1 mM Mg-acetate, 1 mM imidazole, 4 mM CaCl2, 0.2% NP-40, 10 mM β-
mercaptoethanol) were added and mixed with 100 µL of MS-Grade calmodulin beads 
(Stratagene 240106) for 4 h at 4°C. Calmodulin beads were washed three times with 10 
mL of CBB and boiled for 3 min with 100 µL of 3X sample buffer.   
 
4.8. Mass-Spectrometry analysis 
4.8.1. Gel Separation of Proteins, In-Gel Digestion and LC-MS/MS 
Analysis  
 
The TAP eluates were resolved on one-dimensional 10% SDS-PAGE gel of 1-mm 
thickness. The gel was fixed in 50% methanol + 10% acetic acid and stained overnight 
with Colloidal Blue staining kit (Invitrogen LC6025). Different regions were cut out from 
the gel and trypsinized as previously described [236] Peptides were desalted [237] dried 
in a Speed-Vac and resuspended in 7 µL of 0.1% TFA (Trifluoroacetic acid). LC-ESI-
MS/MS of 5µL of each sample was performed on a Fourier transformed-LTQ mass 
spectrometer  (FT-LTQ) (Thermo Electron, San Jose, CA). Peptides separation was 
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performed on a linear gradient from 100% solvent A (5 % ACN (acetonitrile), 0.1% 
formic acid) to 20% solvent B (ACN, 0.1% formic acid) over 20 minutes and from 20% 
to 80% solvent B in 5 minutes at a constant flow rate of 0.3 µL/min on Agilent 
chromatographic separation system 1100 (Agilent Technologies, Waldbronn, Germany) 
where the LC system was connected to a 10.5 cm fused-silica emitter of 100 µm inner 
diameter (New Objective, Inc. Woburn, MA USA), packed in-house with ReproSil-Pur 
C18-AQ 3 µm beads (Dr. Maisch Gmbh, Ammerbuch, Germany) using a high-pressure 
bomb loader (Proxeon, Odense, Denmark).  
Data acquisition mode was set to obtain one MS scan followed by five MS/MS 
scans of the five most intense ions in each MS scan. MS/MS spectra were limited to one 
scans per precursor ion followed by 1 minute of exclusion. MGF file were extracted using 
DTASuperCharge (v.1.19, www.cebi.sdu.dk) while Database search was performed using 
Mascot Daemon already set up with the following parameters: Database NCBInr, 
Taxonomy Mouse (Mus musculuus), enzyme Trypsin, Max missing cleavage 2, fixed 
modification carbamidomethyl (C), variable modification oxidation (M), peptide 
tolerance 10 ppm, MS/MS tolerance 0.5 Da, Instrument ESI-TRAP. The mass 
spectrometry analysis was performed by the Mass spectrometry Unit at IFOM-IEO 
campus. 
 
4.9. Pull-down Assay Using GST Fusion Protein  
4.9.1. GST-Fusion Protein Production and Purification 
Meis1a-GST and Prep1-GST mutant [72] constructs were transformed in 
BL21(DE3)pLysS competent cells (promega, Cat.No. L1191). A single clone was 
inoculated in 10 mL LB medium + Ampicillin sodium salt (100 µg/mL, Sigma Cat.No. 
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A0166-25G) overnight at 37 °C in agitation. The bacterial culture was poured in 100 mL 
of LB medium + Ampicillin sodium salt and grown to OD ≈ 0.8. IPTG was added to the 
final concentration of 0.1 mM to induce GST-fusion proteins induction, for 3 hours at 37 
°C agitating. The bacterial pellet was suspended in 10 mL of ice cold PBS + protease 
inhibitor cocktail (Roche) and was sonicated on ice at power 2,8 for a total of 5 minutes 
with 10 sec intervals. 20% Triton X-100 was added to a final concentration of 1% and 
rotated at 4 ºC for 30 minutes. The lysate was centrifuge at 1300 rpm at 4ºC for 15 
minutes and either used to cross-link to glutatione beads or aliquoted and stored at -80 °C 
for later use. 
 
4.9.2. Cross-Linking GST Fusion Proteins to Glutathione Beads 
40 µL of the 50% Glutathione-Sepharose™ 4B bead suspension (∼ 20 µL of packed 
gel volume) (GE Health care, Cat.No. 17-0756-05) were washed 3 times with PBS prior 
to the use and incubated roughly with 60 µg of the bacterial lysate in 500 µL PBS-T 1% 
(plus protease inhibitors) for 1 hour at 4ºC rotating. The GST-fusion proteins were eluted 
from the beads by boiling for 5 minutes in 20 µL of 2X sample buffer and run on the 10% 
SDS-PAGE gel along with 1 µg, 3 µg, 5 µg, 7 µg and 10 µg of BSA as an internal 
reference. Proteins were visualized by Coomassie brilliant blue staining for 15 minutes at 
room temperature shaking. The staining was followed by de-staning in Coomassie de-
stain solution for 1-2 hours. Finally, the concentration of the induced GST-fusion proteins 
was estimated based on the BSA concentrations. 
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4.9.3. GST-Pull Down Protocol 
60 µg of each GST-fusion protein was bound to 40 µL of the 50% Glutathione-
Sepharose™ 4B bead as previously described. 300 µg of the nuclear lysate was mixed 
with GST-fusion protein, which adsorbed to Glutathione-Sepharose beads. The binding 
reaction was carried out for 1 hour at 4ºC in 1 mL IBB buffer (section 4.6). After 
thoroughly washing, 20 µL of 2X sample buffer was added to each sample and boiled for 
5 minutes. 30 µg of the lysate (as input) along with specifically bound proteins to the 
GST-fusion protein were subjected to 10% SDS–PAGE followed by western blotting 
analysis. 
4.10. Cell Proliferation Assay 
Cells were counted using trypan blue dye and 70000 cells/well were seeded in a 6-
well culture plates. All experiments were performed in triplicate. The day of plating was 
referred as T0 (12 hours post plating). Depending on the experiment, cells were either 
tripsinized and counted on the indicated time points or fixed with 4% paraformaldehyde 
for 10 minutes at room temperature and stained with crystal violet solution (0.1% crystal 
violet in PBS). The plates were air-dried and to solubilize crystal violet, cells were treated 
with a solution of 1% SDS in H2O and 100 µL of each sample was transferred to a 96-
well plate. Absorbance was read at 595 nm on a Victor3™ 1420 multilabel plate counter 
(PerkinElmer). In the last method, the growth was expressed as the value of absorbance at 
a given time point subtracted by the level of absorbance at T0.  
4.11. Cell Cycle Analysis by FACS 
3 × 106 cells were pulsed in medium containing 33 µM BrdU for 45 minutes. Cells 
were harvested and washed well in PBS. The pellet of cells was resuspended in 750 µL 
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PBS and fixed by adding 2250 µL pure ethanol dropwise while vortexing and kept on ice 
for 30 minutes. Cells were then washed in 1 mL PBS + 1% BSA and resuspended in 1 
mL denaturating solution (2N HCl) and incubated at room temperature for 25 minutes. To 
neutralize HCl, 3 mL of 0.1 M Sodium Borate (Na2B4O7 pH 8.5) were added and 
incubated for 2 minutes at room temperature. Cells were washed in 1 mL PBS + 1% BSA 
twice. Pellet of cells was resuspended in 100 µL pure mouse anti-BrdU (BD Biosciences) 
(diluted 1 to 5 in PBS + 1% BSA) and incubated for 1 hour at room temperature light 
protected. Cells were washed in 1 mL PBS + 1% BSA and resuspended in 100 µL FITC-
conjugated anti-mouse IgG (1:50 in PBS +1% BSA). Cells were incubated for 1 hour at 
room temperature, light protected. Cells were washed in 1 mL PBS + 1% BSA and 
resuspended in 1 mL Propidium Iodide (PI) (2.5 µg/mL) + RNase (250 µg/mL) and 
incubated at 4 ºC overnight rotating. The proportion of BrdU-incorporating cells was 
determined with FACSCalibur (BD Biosciences). 
 
4.12. Transformation Assay 
4.12.1. Focus Formation Assay 
5 × 103 cells were plated in 10 cm cell culture dish. The medium was changed every three 
days. After two weeks, the medium was removed and cells were washed once with PBS. 
Colonies were fixed with 4% paraformaldehyde for 10 minutes at room temperature and 
stained with crystal violet solution (0.1% crystal violet, 20% ethanol) for 5 minutes. 
Plates were rinsed twice with dH2O and dried inverted. The visible foci were scored. 
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4.12.2. Soft-Agar Colony Formation Assay (anchorage independent 
growth assay) 
To prepare soft agar dishes, 5% low melting agarose (Gellyphor Euroclone, Cat.No. 
EMR911100) in PBS was autoclaved prior to the use. 36 mL of the complete DMEM 
medium was mixed with 4 mL of 5% low melting agarose. 3 mL of the resulting 0.5% 
agarose/medium mix was poured in each 6 cm dishes to serve as bottom layer. After 
solidifying, cells were counted using tryphan blue dye and 3 × 105 viable cells were 
suspended in 3 mL of complete DMEM medium and added to the 9 mL of 0.4% 
agarose/medium mix. To perform the experiment in triplicate, 12 mL cell suspension was 
poured on the top of the three solidified bottom layer agarose plates (4 mL each). 
Colonies were scored and counted after one week of the incubation.  
 
4.12.3. Allograft Studies in Mice 
7 weeks old Hsd:Athymic Nude-Foxn1nu (Harlan) females were subcutaneously 
inoculated with 1 × 106  infected MEFs, suspended in 100 µL of PBS. Primary tumor 
growth was monitored every 2 to 3 days by caliper. Tumor volume was calculated using 
the following formula: volume = length × width2 × 0.526. Mice were euthanized when the 
tumors were 1.5 cm3 and allografts were recovered for analysis. 5 mice were used for 
each experimental group. Mice were maintained in “Specific Pathogen Free” (SPF) units. 
All experiments were performed according to the guidelines for care and use of 
laboratory animals approved by the institutional ethical animal care committee 
(Institutional Animal Care and Use Committee Project 110/11). 
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4.13. Immunofluorescence and Localization Studies 
40000 cells were plated on poly-D-lysine-coated coverslips in 24 well plates. The 
day after, culturing medium was removed and cells were washed twice with PBS. Cells 
were fixed with in 4% Paraformaldehyde (in PBS) for 10 minutes at room temperature 
followed by 2 washes in PBS each for 10 minutes. Cells were permabilized in 0.5 % 
Triton X-100 (in PBS) for 5 minutes at room temperature. And then washed 3 times in 
PBS each for 5 minutes. To prevent non-specific binding of the antibodies, cells were 
blocked in 2% BSA in PBS (Filtered with 0.45 µm filter) for 1 hour at room temperature. 
Cells were incubated with primary antibody diluted in blocking buffer (anti-Prep1 rabbit 
polyclonal 1:50 Santa Cruz) over night at 4 °C. Cells were washed 3 times, 5 minutes 
each and then incubated with Donkey anti-rabbit Cy5-conjugated secondary antibody 
(Alexa Fluor 647) for 90 minutes at room temperature (light protected). After 3 washes 
with PBS 5 minutes each, DAPI staining was performed (1:5000 of 1 mg/mL stock 
concentration, Sigma) for 5 minutes at room temperature. Coverslips were washed 3 
times with PBS and mounted with Mowiol medium. Images were acquired either with a 
wide field BX61 (Olympus) motorized fluorescence microscope or a confocal laser 
microscopy (Leica TCS SP2). Images were analyzed with ImageJ software developed by 
American National Institute of Health (NIH). 
4.14. Total RNA Extraction and cDNA Synthesis 
RNeasy mini kit (Qiagen) was used to perform all RNA extractions, following the 
manufacture’s instructions. Total RNA was quantified by spectrophotometer (Nanodrop). 
1 µg of total RNA of each sample was retro-transcribed using Supercript ™ III First-
Strand Synthesis System for RT-PCR Kit (Invitrogen), using random primers. Each 
reaction mix was composed of: 
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Component                              
- Total RNA  
- 10mM dNTPmix                          
- Random hexamers                        
- RNase-free water                          
Amount 
1 µg 
1 µL 
50-250 ng/µL 
Up to 13 µL 
RNA/primer mixture was incubated at 65 °C for 5 minutes and then placed on ice for at 
least 1 minute. In a separate tube the following 2X reaction mix was prepared. 
Component  
5X First-Strand buffer                  
0.1 M DTT                                   
0.2 M RNaseOUT™ (40U/µL)                 
Amount for 1 reaction 
4 µL 
2 µL 
1 µL 
7 µL of the 2X reaction mix was added to each RNA/primer mixture. 1 µL of 
Superscript ™ III RT was added to each sample. For minus RT controls 1 µL of RNase-
free water was added. The reactions have been performed in 3 steps: 5 minutes at 25 °C, 
50 minutes at 50 °C and 15 minutes at 70 °C. 
 
 
4.15. Semiquantitative PCR 
1 µL of cDNA was used as template to perform semiquantitative PCR using primers 
listed below in a reaction volume of 50 µL composed of: 
Component                                              
5X Green GoTaq® Reaction buffer               
10 mM dNTP mix                                          
10  µM Forward primer                                  
10 µM Reverse primer                                    
25 mM MgCl2                                                 
Amount 
2.5 µL 
0.5 µL 
0.6 µL 
0.6 µL 
1.5 µL 
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GoTaq® DNA Polymerase (5 U/ µl) 
Template  
H2O 
0.125 µL 
1 µL 
Up to 25 µL 
 
PCR was carried out either on EPENDORF mastercycler gradient or GeneAmp 
PCR system a700 using a pre-PCR step of 2 minutes at 97°C, followed by 28 cycles of 30 
sec at 97 °C, 30 sec at X °C, 30 sec at 72 °C and final extension 10 minutes at 72 °C. For 
Prep1 mutants (∆ proteins) the extension was performed for 1 minute at 72 °C. 10 µL of 
the PCR product was mixed with 6X loading dye and run on a 1 % agarose gel in TAE 
running buffer. 
Primers sets Tm  °C Sequences (5´→3´)                                              
Prep1 Forward Primer  
Prep1 Reverse Primer  
Prep1∆HR12 Forward Primer  
Prep1∆HR12 Reverse Primer  
Prep1∆HD Forward Primer  
Prep1∆HD Reverse Primer  
Prep1∆C Forward Primer  
Prep1∆C Reverse Primer  
Prep1 Forward Primer  
Prep1 Reverse Primer  
Meis1 Forward Primer  
Meis1 Reverse Primer  
Pbx1a/b Forward Primer  
Pbx1a/b Reverse Primer  
Pbx2 Forward Primer  
Pbx2 Reverse Primer  
Gapdh Forward Primer  
Gapdh Reverse Primer  
62.5 
 
62.5 
 
62.5 
 
62.5 
 
60 
 
65 
 
55 
 
62 
 
58 
ATGATGGCTACACAGACATTAAG   
CTACTGCAGGGAGTCACTGTTC 
ATGATGGCTACACAGACATTAAG   
CTACTGCAGGGAGTCACTGTTC 
ATGATGGCTACACAGACATTAAG   
CTACTGCAGGGAGTCACTGTTC  
ATGATGGCTACACAGACATTAAG   
TTACATTGGCTGAAGAATTGGTC 
ACAGACGCTAAGTATAGACAG 
 AATCTGCTGGGATTGCACA 
GTAATGGACGGTCAGCAGCAC 
GTGCACTCATTGTCGGGTCTC 
CAGAGCCACCAATGTGTC 
TCCGTCACTGTATCCTCC 
GCCACAGCCGCACCAGCTCT 
GGACACCCCACTCTCCCTG 
GTCTACATGTTCCAGTATGACTCC 
AGTGAGTTGTCATATTTCTCGTGGT 
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Prep1 wt MEFs
emPAI
Mascot ScorePrep1 i/i MEFs
emPAIMascot ScorePrep1 i/i MEFs re-expressing Prep1emPAI
Mascot Score
Meis1
0.28
254
Meis1
0.28
221
Meis1
0.13
153
Pbx1
0.37
270
Pbx1
0.46
303
Pbx1
0.37
260
Pbx2
0.28
232
Pbx2
0.23
176
Pbx2
0.28
242
Ddx3x
4.04
2430
Ddx5
2.72
1603
fibronectin precursor 
0.7
3056
fibronectin precursor 
0.62
2803
fibronectin precursor 
0.66
29500
plectin 1 
0.01
110
plectin 1 
0.03
241
plectin 1 
0.18
1386
p160 myb-binding protein
0.04
149
p160 myb-binding protein
0.04
144
p160 myb-binding protein
0.16
444
Ras GTPase-activating-like protein    0.04
144
Ras GTPase-activating-like protein   0.29
970
RNA-binding protein FUS 
0.72
532
RNA-binding protein FUS 
0.44
377
Cux homeodomain protein 
0.05
166
SNW domain-containing protein
0.17
183
SNW domain-containing protein
0.37
358
Cald1 protein 
9.8
749
Gamma-actin
1.72
907
Gamma-actin
7.64
1679
nucleolar RNA helicase II/Gu
0.11
137
nucleolar RNA helicase II/Gu
0.43
642
Tables 
Table 2.1. The list of co-purified proteins with Mesi1a-TAP, analyzed by mass-
spectrometry 
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